

CV-Dr. Ghulam Md Ashraf

Dr. Ghulam Md Ashraf, PhD, FRSM, MRSB

Associate Professor

King Fahd Medical Research Centre

King Abdulaziz University, Jeddah, Saudi Arabia

Email: gashraf@kau.edu.sa, ashraf.gm@gmail.com

Contact no.: +966596738355

Specialization: Biochemistry **Research interest:** Neurology



Total publications	293	PhD supervision (ongoing)	3
H-index (Google scholar)	39	Master supervision (completed)	1
i10-index (Google scholar)	146	Master supervision (ongoing)	1
Citations (Google scholar)	5762	Bachelor supervision (completed)	7
Publons verified editor records	235	Thesis examination	6
Publons verified reviewer records	464	Research grant assessment	4
Researchgate score	51.43	Scientific meetings	22
Research projects (ongoing)	16 (13 PI, 3 CoI)	Books as author and editor	7
Research projects (completed)	7 (4 PI, 3 CoI)	Guest editor of special issues	16
PROFESSIONAL MEMBERSHIPS	1. Fellow of the Royal Society of Medicine (FRSM, Member No: 00723087) 2. Member of the Royal Society of Biology (MRSB, Member No: P0139900) 3. Member of American Society for Biochemistry and Molecular Biology (Member id: 79453)		
EDITORIAL EXPERIENCE	1. Associate Editor in Journal of Advanced Research 2. Senior EBM in Scientific Reports 3. Academic Editor in PLOS one 4. EBM in Frontiers in Pharmacology 5. EBM in Frontiers in Bioscience-Landmark 6. Section Editor in Current Neuropharmacology		
AWARDS & HONORS	1. Listed in Top 2% Scientists Worldwide, announced by Elsevier BV (Baas et al., 2021) 2. Listed in Marquis Who's Who in the world (2020) 3. Publons/Web of Science Top reviewers award in Cross-Field award (2019) 4. Publons/Web of Science Top reviewers award in Biology and Biochemistry award (2019)		

FEATURED PUBLICATIONS: *Corresponding author

- Ashraf GM^{*,#}**, Chatzichronis S[#], Alexiou A[#], Kyriakopoulos N, Alghamdi BS, Tayeb HO, Alghamdi JS, Khan W, Jalal MB, Atta HM. BrainFD: measuring the intracranial brain volume with fractal dimension. **Frontiers in Aging Neuroscience (2021) (Accepted, in press). [Impact Factor: 5.750]**
- Ashraf GM^{*}**, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO, Tarazi FI. Empagliflozin effectively attenuates olanzapine-induced body weight gain in female Wistar rats. **Frontiers in Pharmacology (2021) 12:578716. [Impact Factor: 5.810]**
- Ashraf GM^{*}**, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO, Tarazi FI. Standardizing the effective correlated dosage of Olanzapine and Empagliflozin in female Wistar rats. **Current Gene Therapy (2021) 21(1):53-59. [Impact Factor: 4.391]**
- Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, **Ashraf GM^{*}**. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. **Seminars in Cancer Biology (2021) (Accepted, in press). [Impact Factor: 15.707]**
- Bhardwaj S, Kesari KK, Rachamalla M, Mani S, **Ashraf GM**, Jha SK, Kumar P, Ambasta RK, Dureja H, Devkota HP, Gupta G, Chellappan DK, Singh SK, Dua K, Ruokolainen J, Kamal MA, Ojha S, Jha NK. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. **Journal of Advanced Research (2021) (Accepted, in press). PMID: [Impact Factor: 10.479]**
- Uddin MS, Tewari D, Mamun AA, Kabir MT, Niaz K, Wahed MIW, Barreto GE, **Ashraf GM^{*}**. Circadian and sleep dysfunction in Alzheimer's disease. **Ageing Research Reviews (2020) 60:101046. [Impact Factor: 10.895]**
- Ullah MF, Ahmad A, Bhat SH, Abu-Duhier FM, Barreto GE, **Ashraf GM^{*}**. Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders. **Neuroscience and Biobehavioral Reviews (2019) 102:95-105. [Impact Factor: 8.989]**
- Ashraf GM**, Tarasov VV, Makhmutova A, Chubarev VN, Avila-Rodriguez M, Bachurin SO, Aliev G. The possibility of an infectious etiology of Alzheimer disease. **Molecular Neurobiology (2019) 56:4479-4491. [Impact Factor: 5.590]**
- Ashraf GM^{*}**, Baesa SS. Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders. **Frontiers in Neuroscience (2018) 12:430. [Impact Factor: 4.677]**

CV-Dr. Ghulam Md Ashraf

Orcid: <https://orcid.org/0000-0002-9820-2078>

Researchgate: https://www.researchgate.net/profile/Ghulam_Ashraf2

Scopus: <https://www.scopus.com/authid/detail.uri?authorId=16444016700>

Publons: <https://publons.com/author/453063/dr-ghulam-md-ashraf#profile>

Google scholar: <http://scholar.google.com/citations?user=-fOCOTQAAAAJ&hl=en>

Linkedin: <https://www.linkedin.com/in/ghulam-md-ashraf-phd-frsm-mrsb-5b13a41ba/>

CURRENT POSITIONS:

Oct 2017-Now: Associate Professor, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.

Teaching (graduate and post-graduate): Biochemistry, Clinical biochemistry, Medical Biochemistry, Medical Laboratory Technology, Molecular Biology, Neurology, Structural Biology.

Research: My primary fields of research are biochemistry and neurology, currently focusing on understanding the molecular and behavioral mechanism of effects of anti-diabetic drugs in psychotic and dementia conditions. My lab is currently investigating the effect of anti-diabetic drugs in dementia, and their role in possible attenuation/reversal of anti-psychotic drugs induced weight gain in psychotic conditions. We are also investigating molecular and behavioral mechanisms of novel therapeutic combinations in multiple sclerosis and Alzheimer's disease.

Jan 2016-Now: Honorary Faculty Member, Novel Global Community Educational Foundation (NGCEF), Australia.

Dec 2017-Now: Visiting Scientist, Glocal University, India.

Nov 2020-Now: Visiting Scientist, China Ethnic Medical Association, China.

PAST POSITIONS:

Jan 2012-Oct 2017: Assistant Professor, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.

Teaching (graduate and post-graduate): Biochemistry, Clinical biochemistry, Medical Biochemistry, Medical Laboratory Technology, Molecular Biology, Neurology, Structural Biology.

Research: My prime field of research during position was investigating the role of proteomics and nanotechnological tools in chronic diseases like neurology and cancer.

July 2010-Jan 2012: Lecturer, Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India.

Teaching (graduate and post-graduate): Biochemistry, Enzymology, Enzyme Technology, Intellectual Property Rights, Molecular Biology, Neurology, Recombinant DNA Technology, Structural Biology.

Research: My prime focus of research during this position was purification and characterization of proteins.

EDUCATIONAL QUALIFICATIONS:

2006-2010: PhD (Biochemistry), Aligarh Muslim University, Uttar Pradesh, India.

Thesis title: Purification and characterization of soluble β -galactoside binding lectins from mammalian heart.

2004-2006: M.Sc. (Biochemistry, 74.83%), Aligarh Muslim University, Uttar Pradesh, India.

2001-2004: B.Sc. (Biochemistry, 70.87%), Aligarh Muslim University, Uttar Pradesh, India.

2006-2009: PGDBA (Operations Management, 66.6%), Symbiosis Centre of Distance Learning, Pune, India.

RESEARCH GRANTS:

Ongoing:

1. Principal investigator in Institutional Funding Program for Research and Development – major research project (Grant no.: IFPRC-196-141-2020) titled '*Virtual screening and validation of novel drugs based on tibolone's structure for targeting lipid metabolism*' funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Proposed funding amount: SAR 300,000)
2. Co-investigator in Institutional Funding Program for Research and Development – major research project (Grant no.: IFPRC-168-141-2020) titled '*Investigation of prophylactic and therapeutic effects of novel nano-formulations in neurodegenerative disorders*' funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Proposed funding amount: SAR 300,000)
3. Principal investigator in Institutional Funding Program for Research and Development –research program path (Grant no.: IFPIP-1536-141-1442) titled '*Exploring the Molecular interactions of fluoxetine with human transferrin: In-silico and in vitro insight*' funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Proposed funding amount: SAR 35,000)
4. Principal investigator in Institutional Funding Program for Research and Development –review program path (Grant no.: IFPRP-586-141-1442) titled '*Caffeic acid: a potential therapeutic in the past, present & future*' funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Proposed funding amount: SAR 35,000)
5. Principal investigator in Institutional Funding Program for Research and Development - research program path (Grant no.: IFPHI-124-141-2020) titled '*Gene-disease association of Galectin-1 using random walk with restart algorithm and its prioritization*' funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 200,000).
6. Co-investigator in Institutional Funding Program for Research and Development - research program path (Grant no.: IFPHI-285-130-2020) titled '*Analysis of interaction between odorant receptors and flexible spike of SARS CoV-2- key to loss of smell*' funded by the Vice Presidency of Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 200,000).
7. Principal investigator in Knowledge Excellence Program (Grant no. KEP-1-141-41) titled '*Investigation of protein biomarkers as potential therapeutic agents of neurodegenerative disorder patients in Saudi Arabia*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 80,000).
8. Principal investigator in Knowledge Excellence Program (Grant no.: KEP-2-141-38) titled '*Understanding the molecular and behavioral mechanism of effects of newest antidiabetic drugs in dementia patients*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 90,000).

9. Co-investigator in Knowledge Excellence Program (Grant no. KEP-36-130-41) titled '*Development of a new class of nitrogen and sulphur containing multitarget MAO-B inhibitors: A new paradigm of neurodegenerative disorders*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 80,000).
10. Principal investigator in General Research Program (Grant no. G: 302-141-1441) titled '*Understanding the psychological effect of anti-diabetic drugs in Alzheimer's disease*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 45,000).
11. Principal investigator in Distinct Research Study (Grant no.: DF -538-141-1441) titled '*Botrytis cinerea alcohol dehydrogenase mediates fungal development, environmental adaptation, and pathogenicity*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 35,000).
12. Principal investigator in Distinct Research Study (Grant no.: DF -776-141-1441) titled '*Drug repurposing against buffalo heart galectin-1 (BjHG-1) using simulation-based studies*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 35,000).
13. Principal investigator in High Quality/Impact Research Publication Initiative (Grant no.: HIQI-49-2019) titled '*Structural modeling and measurement of brain volume*' funded by the Vice Presidency for Graduate Studies and Scientific Research, Research and Development Office, King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 1,10,000).
14. Principal investigator in General Research Program (Grant no.: G: 1440 -141-1346) titled '*Bio-physico-chemical properties of membranes in impaired mitochondrial dynamics due to neurodegeneration*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 46,000).
15. Principal investigator in General Research Program (Grant no.: G -1438 - 141 - 417) titled '*Assessment of alterations in the expression pattern of Galectin-3 in atherosclerotic patients*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 40,800).
16. Principal investigator in Distinct Research Study (Grant no.: G -141-954-D1435) titled '*A comparative study of buffalo heart galectin-1 with goat heart galectin-1 to identify a preferred probe for molecular recognition studies*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 50,000).

Completed:

1. Principal investigator in Knowledge Excellence Program (Grant no.: KEP-2-141-40) titled '*Understanding the behavioral and molecular mechanism of effects of antipsychotic and antidiabetic drugs in psychotic patients with diabetic condition*' funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 90,000).
2. Principal investigator in General Research Program (Grant no.: G -1439 - 141 - 670) titled '*Computational Analysis of Noncoding RNAs in Alzheimer's Disease*' funded by the

Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 25,000).

3. **Co-investigator in General Research Program (Grant no. G: 418-141-1438)** titled '*Novel drug designing targeting key signalling protein PI3K kinases to combat cancer in Saudi Arabia*' funded by the **Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 42,800).**
4. **Co-investigator in Research Project (Grant no.: 12-BIO-3082-03)** titled '*Structural and functional studies of lactoperoxidase, an antimicrobial protein from camel milk*' funded by **Strategic Technologies Research Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia (Funded amount: SAR 16,76,000).**
5. **Principal investigator in General Research Program (Grant no.: G -1436 - 141 - 412)** titled '*Studies on immunological, oxidative burst and degranulation properties of a galectin-1 purified from goat (Capra hircus) heart*' funded by the **Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 78,000).**
6. **Principal investigator in Distinct Research Study (Grant no.: 141-764-D1435)** titled '*Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders*' funded by the **Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 50,000).**
7. **Co-investigator in General Research Program (Grant no.: G-1435-141-528)** titled '*A putative associations of Interleukin-1 β and interleukin-10 gene polymorphism with coronary artery diseases in Saudi population*' funded by the **Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia (Funded amount: SAR 1,48,000).**

SUPERVISION:

S.N.	Name of the student	Id no.	Degree	Status
1	Shmmon Ahmad	GU18R0782	Ph.D.	Ongoing
2	Dharmender	GU18R0783	Ph.D.	Ongoing
3	Kholoud Marzooq Al-Otaibi	1801055	Ph.D.	Ongoing
4	Rahaf Saeed Al-Dhahri	1900159	Master	Ongoing
5	Wedad Ahmad Hakami	1601938	Master	Awarded
6	Ahmed Salem Al-Awlaqi	1638368	Bachelor	Awarded
7	Mahmoud Fouad Sayed	1535344	Bachelor	Awarded
8	Ahmed Marwan Alfee	1536485	Bachelor	Awarded
9	Thamir Sami Alfadda	1635078	Bachelor	Awarded
10	Zayed Ali Alotaibi	1637066	Bachelor	Awarded
11	Faisal Mustafa Baothman	1635602	Bachelor	Awarded
12	Abdulrahman Saleh Al-Harbi	1801055	Bachelor	Awarded

PROFESSIONAL AFFILIATIONS:

1. Fellow of the Royal Society of Medicine (FRSM, Member No: 00723087)
2. Member of the Royal Society of Biology (MRSB, Member No: P0139900)
3. Member of American Society for Biochemistry and Molecular Biology (Member id: 79453)
4. Member of Science Advisory Board (Member id: gashraf_544)

ACHIEVEMENTS/AWARDS/HONORS:

- Listed in **Top 2%** Scientists Worldwide, announced by Elsevier BV (Baas et al., 2021).
- Expertscape World Expert (**top 0.031%**) in Alzheimer's disease (Ranked **1st** in Saudi Arabia, **11th** in Asia, and **52nd** Worldwide) (2021).
- Expertscape World Expert (top 0.0033%) in Nervous System Diseases (Ranked **1st** in Saudi Arabia, **4th** in Asia, and **13th** Worldwide) (2021).
- Appointed as Member of Scientific Committee at KFMRC, KAU, KSA (2021).
- Elected as Fellow of the Royal Society of Medicine (FRSM, No: 00723087) (2020).
- Approved as a subject of biographical record in Marquis Who's Who in the World (2020).
- Elected as Member of American Society for Biochemistry and Molecular Biology (2020).
- Elected as Member of the Royal Society of Biology (MRSB, No: P0139900) (2020).
- Publons/Web of Science Top reviewers award in Biology and Biochemistry award (2019).
- Publons/Web of Science Top reviewers award in Cross-Field award (2019).
- Promoted as Associate Professor, KFMRC, KAU, KSA (2017).
- Appointed as Head of Molecular Biology Lab at KFMRC, KAU, KSA (2015-2017).
- Chaired Geriatric-1 session at GeNeDis, Ionian University, Greece (2014).
- Coordinator and member of KFMRC publication committee, KAU, KSA (2012-2013).
- Appointed as Lecturer in Amity University, Lucknow, India (2010).
- Job offer letter from SDL Fine Chemicals to join as Senior Molecular Biologist (2010).
- Fellowship for Ph.D. scholars from UGC, New Delhi, India (2007-2010).
- JRF for research project funded by Ayush, India (2006).
- Merit scholarship from Bharat Sewa Trust, AMU, India (2006).
- Waheeda Ahmad Endowment Scholarship, AMU, India (2006).
- Qualified a national level aptitude test, GATE, India (2006).
- Merit Scholarship from AMU Alumni Association, Michigan (2005).
- First Prize in Scientific Model Competition on National Science Day, AMU, India (2005).
- Proctorial Monitor, AMU, India (2003).

PUBLICATIONS:

* Corresponding author # Equally contributing author

Research articles:

1. Ashraf GM^{*,#}, Chatzichronis S[#], Alexiou A[#], Kyriakopoulos N, Alghamdi BS, Tayeb HO, Alghamdi JS, Khan W, Jalal MB, Atta HM. BrainFD: measuring the intracranial brain volume with fractal dimension. **Frontiers in Aging Neuroscience (2021) (Accepted, in press). PMID: [Impact Factor: 5.750]**
2. Ashraf GM^{*}, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO, Tarazi FI. Empagliflozin effectively attenuates olanzapine-induced body weight gain in female Wistar rats. **Frontiers in Pharmacology (2021) 12:578716. PMID: 33953666 [Impact Factor: 5.810]**
3. Ashraf GM^{*}, Alghamdi BS, Alshehri FS, Alam MZ, Tayeb HO, Tarazi FI. Standardizing the effective correlated dosage of olanzapine and empagliflozin in female Wistar rats. **Current Gene Therapy (2021) 21(1):53-59. PMID: 33183202 [Impact Factor: 4.391]**
4. Jiang H[#], Ashraf GM[#], Liu M, Zhao K, Wang Y, Wang L, Xing J, Alghamdi BS, Li Z, Liu R. Tilianin ameliorates cognitive dysfunction and neuronal damage in rats with vascular dementia via p-CaMKII/ERK/CREB and ox-CaMKII-dependent MAPK/NF- κ B pathways. **Oxidative Medicine and Cellular Longevity (2021) 6673967. PMID: [Impact Factor: 6.543]**
5. Chavda V, Patel S, Alghamdi BS, Ashraf GM. Endothelin-1 induced global ischaemia in adult zebrafish: A model with novel entity of stroke research. **Journal of Chemical Neuroanatomy. (2021) 118:102025. PMID: 34520802 [Impact Factor: 3.052]**
6. Rajput R, Chavda V, Patel SS, Barreto GE, Ashraf GM. efonidipine exerts cerebroprotective effect by down-regulation of TGF- β /SMAD-2-dependent signaling pathway in diabetic rats. **Journal of Molecular Neuroscience (2021) 71(9):1884-1896. PMID: 34554398 [Impact Factor: 3.444]**
7. Rahman MM, Islam F, Parvez A, Azad MAK, Ashraf GM Ullah MF, Ahmed M. Phytochemical investigation and neuropharmacological potential of *Citrus limon L.* (lemon) seed extracts studied in vivo on swiss albino mice. **Journal of Integrative Neuroscience (2021) (Accepted, in press). PMID: [Impact Factor: 2.117]**
8. Barreto GE, Gonzalez J, Reiner Ž, Jamialahmadi T, Echeverria V, Ashraf GM, Sahebkar A. In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). **Chemico-Biological Interactions. (2021) 345:109528 PMID: 34022192 [Impact Factor: 5.192]**
9. Singla RK, Ashraf GM, Ganash M, Bhat GV, Shen B. Physicochemical, interaction & topological descriptors vs. hMAO-A inhibition of aplysinopsin analogs: A boulevard to the discovery of semi-synthetic anti-depression agents. **Current Drug Metabolism (2021) (Accepted, in press). PMID: [Impact Factor: 3.731]**
10. AlShorman O, Masadeh M, Heyat MBB, Akhtar F, Almahasneh H, Ashraf GM, Alexiou A. Frontal lobe real-time EEG analysis using machine learning techniques for mental stress detection. **Journal of Integrative Neuroscience (2021) (Accepted, in press). PMID: [Impact Factor: 2.117]**
11. Kushwaha P, Singh V, Somvanshi P, Bhardwaj T, Barreto GE, Ashraf GM, Mishra BN, Chundawat RS, Haque S. Identification of BACE1 inhibitors for treating Alzheimer's

- disease: evidence from in silico molecular docking and simulation studies. **Journal of Molecular Modeling** (2021) (Accepted, in press). PMID: 33517514 [Impact Factor: 1.810]
12. Harakeh S, Qari MH, Ramadan WS, Jaouni SKA, Muhayawi MSA, Amri TA, **Ashraf GM**, Bharali DJ, Mousa SA. Novel nano-formulations of ellagic acid are promising in restoring oxidative homeostasis in rat brains with Alzheimer's disease. **Current Drug Metabolism** (2021) (Accepted, in press). PMID: 33327909 [Impact Factor: 3.731]
 13. Kabir MT, Samiha M, Yasmin H, Rahman MS, Rahman MS, **Ashraf GM**, Akter R. Free radical scavenging, thrombolytic and cytotoxic effects of the medicinal herb, *Crassocephalum crepidioides*. **Research Journal of Pharmacy and Technology** (2021) (Accepted, in press). PMID: 33327909 [Impact Factor: 2.277]
 14. Zeng L, Jiang HL, **Ashraf GM**, Li ZR, Liu R. MicroRNA and mRNA profiling of cerebral cortex in a transgenic mouse model of Alzheimer's disease by RNA sequencing. **Neural Regeneration Research** (2021) 16(10):2099-2108. PMID: 33642400 [Impact Factor: 5.135]
 15. Kumar R, Khan FU, Sharma A, Siddiqui MH, Aziz IBA, Kamal MA, **Ashraf GM***, Alghamdi BS, Uddin MS. A deep neural networks-based approach for prediction of mutagenicity of compounds. **Environmental Science and Pollution Research** (2021) (Accepted, in press). PMID: 33895950 [Impact Factor: 4.223]
 16. Rakib F, Ahmed T, Al-Saad K, Ullah E, Barreto GE, **Ashraf GM***, Ali MHM. Biomolecular alterations in acute traumatic brain injury (TBI) using Fourier transform infrared (FTIR) imaging spectroscopy. **Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy** (2020) 248:119189. PMID: 33277210 [Impact Factor: 4.098]
 17. Dhasmana A, Kashyap VK, Dhasmana S, Kotnala S, Haque S, **Ashraf GM**, Jaggi M, Yallapu MM, Chauhan SC. Neutralization of SARS-CoV-2 spike protein via natural compounds: a multi layered high throughput virtual screening approach. **Current Pharmaceutical Design** (2020) 26(41):5300-5309. PMID: 32867645 [Impact Factor: 3.116]
 18. Potttoo FH, Tabassum N, Javed MN, Nigar S, Sharma S, Barkat MA, Harshita, Alam MS, Ansari MA, Barreto GE, **Ashraf GM***. Raloxifene potentiates the effect of fluoxetine against maximal electroshock induced seizures in mice. **European Journal of Pharmaceutical Science** (2020) 15;146:105261. PMID: 32061655 [Impact Factor: 4.384]
 19. Ahmad F, Haque S, Ravinayagam V, Ahmad A, Kamli MR, Barreto GE, **Ashraf GM**. Developmental lead (Pb)-induced deficits in redox and bioenergetic status of cerebellar synapses are ameliorated by ascorbate supplementation. **Toxicology** (2020) 12;440:152492. PMID: 32407874 [Impact Factor: 3.547]
 20. Shah P, Chavda V, Patel S, Bhadada S, **Ashraf GM**. Promising anti-stroke signature of voglibose: investigation through in-silico molecular docking and virtual screening in *in-vivo* animal studies. **Current Gene Therapy** (2020) 20(3):223-235. PMID: 33054705 [Impact Factor: 2.431]
 21. Saeed M, Kushvaha V, Faisal SM, Verma R, Ahmad I, Mustafa H, Ganash M, Kamal MA, **Ashraf GM***. A study on serological reactivity profile of different antigen preparations with bancroftian filariasis human infection sera. **Protein & Peptide Letters** (2020) 27(9):841-850. PMID: 32096736 [Impact Factor: 1.168]

22. Rehan M, Mahmoud M, Tabrez S, Hassan HMA, **Ashraf GM**. Exploring flavonoids for potential inhibitors of a cancer signaling protein PI3K γ kinase using computational methods. **Anticancer research** (2020) 40(8):4547-4556. PMID: 2727785 [Impact Factor: 1.935]
23. Shoaib A, Badruddeen, Dixit RK, Ahmad K, Ganash M, Barreto GE, **Ashraf GM***, Siddiqui HH. Beneficial effects of n-hexane bark extract of *Onosma echioides* L. on diabetic peripheral neuropathy. **Journal of Cellular Biochemistry** (2019) 20:16524-16532. PMID: 31099436 [Impact Factor: 3.448]
24. Khan DI, Beig FK, Ahmad Z, **Ashraf GM***. Sputum negative tubercular adults spread infection and disease to their household children. **Biosciences Biotechnology Research Asia** (2019)16(3):581-594. PMID: [Impact Factor:]
25. Aziz ZAA, Nasir HM, Ahmad A, Hamidah MSS, Ahmad H, Noor MHM, Rafatullah M, Khatoon A, Kausar MA, Ahmad I, Khan S, Al-Shaeri M, **Ashraf GM***. Enrichment of eucalyptus oil nanoemulsion by micellar nanotechnology: transdermal analgesic activity using hot plate test in rats assay. **Scientific Reports** (2019) 9:13678. PMID: 31548590 [Impact Factor: 4.011]
26. Elshareef SHM, Abdalla M, Eltayb WA, El-Arabey AA, Ganash M, Alshammari FD, Barreto GE, **Ashraf GM***. Molecular cloning, expression, purification, and functional characterization of SP-22 gene from *Bombyx mori*. **Journal of Cellular Biochemistry** (2019) 120(9):15594-15603. PMID: 31099441 [Impact Factor: 3.448]
27. Baez-Jurado E, Guio-Vega G, Hidalgo-Lanussa O, González J, Echeverria V, **Ashraf GM**, Sahebkar A, Barreto GE. Mitochondrial neuroglobin is necessary for protection induced by conditioned medium from human adipose-derived mesenchymal stem cells in astrocytic cells subjected to *scratch* and metabolic injury. **Molecular Neurobiology** (2019) 56(7):5167-5187. PMID: 30536184 [Impact Factor: 4.586]
28. Sheikh IA, Jiffri EH, **Ashraf GM**, Kamal MA. Structural insights into the camel milk lactoperoxidase: Homology modeling and molecular dynamics simulation studies. **Journal of Molecular Graphics and Modelling** (2019) 86:43-51. PMID: 30326373 [Impact Factor: 1.863]
29. Tahir RA, Wu H, Javed N, Khalique A, Khan SAF, Mir A, Ahmed MS, Barreto GE, Qing H, **Ashraf GM***, Sehgal SA. Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. **Journal of Cellular Physiology** (2019) 234(8):13263-13276. PMID: 30569503 [Impact Factor: 4.522]
30. Zaidi SK, Ansari SA, Tabrez S, **Ashraf GM**, Shakil S, Alam Jafri MA, Naseer MI, Banu N, Al-Qahtani M. Hepato-protective effect of *Allium sativum* against immobilization stress in rats. **Pakistan Journal of Pharmaceutical Sciences** (2019) 32(2):521-528. PMID: [Impact Factor: 0.596]
31. Jurado-Coronel JC, Loaiza AE, Díaz JE, Cabezas R, **Ashraf GM**, Sahebkar A, Echeverria V, González J, Barreto GE. (E)-nicotinaldehyde O-cinnamyloxime, a nicotine analog, attenuates neuronal cells death against rotenone-induced neurotoxicity. **Molecular Neurobiology** (2019) 56:1221-1232. PMID: 29881944 [Impact Factor: 4.586]
32. Vesga-Jiménez DJ, Hidalgo-Lanussa O, Baez-Jurado E, Echeverria V, **Ashraf GM**, Sahebkar A, Barreto GE. Raloxifene attenuates oxidative stress and preserves mitochondrial function in astrocytic cells upon glucose deprivation. **Journal of Cellular Physiology** (2019) 234(3):2051-2057. PMID: 30246411 [Impact Factor: 4.522]

33. Baig MH, Rashid I, Srivastava P, Ahmad K, Jan AT, Rabbani G, Choi D, Barreto GE, **Ashraf GM**, Lee EJ, Choi I. NeuroMuscleDB: a database of genes associated with neuromuscular diseases, aging and neurodegeneration. **Molecular Neurobiology** (2019) 56(8):5835-5843. **PMID: 30684219 [Impact Factor: 4.586]**
34. Makara-Studzinska M, Somasundaram S, **Ashraf GM**, Gogacz M, Madej A, Izydorczyk B, Leszek J, Lebedeva SA, Choubarov V, Tarasov VV, Kirkland E, Aliev G. Assessment of psychosocial functioning of mothers of children with diabetes mellitus compared to mothers of healthy children. **BioMed Research International** (2019) 6821575:1-10. **PMID: 31093501 [Impact Factor: 2.197]**
35. **Ashraf GM***, Ganash M, Athanasios A. Computational analysis of non-coding RNAs in Alzheimer's disease. **Bioinformation** (2019) 15(5):351-357. **PMID: 31249438 [Impact Factor:]**
36. Yadav BS, Chaturvedi N, Yadav PK, Marina N, Ganash M, Barreto GE, **Ashraf GM***, Ahmad K, Baig MH. Protein modeling, molecular network and molecular dynamics study of newly sequenced interleukin-18 (IL-18) gene in *Mus musculus*. **Journal of Cellular Physiology** (2019) 234(8):14285-14295. **PMID: 30624775 [Impact Factor: 4.522]**
37. Pottoo FH, Tabassum N, Javed MN, Nigar S, Rasheed R, Khan A, Barkat MA, Alam MS, Maqbool A, Ansari MA, Barreto GE, **Ashraf GM**. The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against pilocarpine-induced status epilepticus and temporal lobe epilepsy. **Molecular Neurobiology** (2019) 56:1233-1247. **PMID: 29881945 [Impact Factor: 4.586]**
38. Stylianos C, Athanasios A, Panagiota S, Vasileios M, Vasileios T, Perveen A, **Ashraf GM***. Neurocognitive assessment software for enrichment sensory environments. **Journal of Proteomics & Bioinformatics** (2019), 12(1):18-28. **PMID: [Impact Factor:]**
39. Begum MM, Uddin MS, Rithy JF, Kabir J, Tewari D, Islam A, **Ashraf GM**. Analyzing the impact of soft, stimulating and depressing songs on attention among undergraduate students: a cross-sectional pilot study in Bangladesh. **Frontiers in Psychology** (2019) 10:61. **PMID: 30804845 [Impact Factor: 2.089]**
40. Ashraf JM, Ansari MZ, Fatma S, Abdullah SMS, Iqbal J, Madkhali A, Hamali AH, Ahmad S, Jerah A, Echeverria V, Barreto G, **Ashraf GM***. Inhibiting effect of zinc oxide nanoparticles on advanced glycation products and oxidative modifications: A potential tool to counteract oxidative stress in neurodegenerative diseases. **Molecular Neurobiology** (2019) 55:7438-7452. **PMID: 29423819 [Impact Factor: 4.586]**
41. **Ashraf GM***, Baesa SS. Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders. **Frontiers in Neuroscience** (2018) 12:430. **PMID: 30008660 [Impact Factor: 3.648]**
42. Mishchenko DV, Neganova ME, Klimanova EN, Sashenkova TE, Allayarova UY, Konovalova NP, Shevtsova EF, Vystorop IV, Tarasov VV, Chubarev VN, Samsonova AN, **Ashraf GM**, Barreto G, Yarla NS, Aliev G. Chemosensitizing activity of histone deacetylases inhibitory cyclic hydroxamic acids for combination chemotherapy of lymphatic leukemia. **Current Cancer Drug Targets** (2018) 18(4):365-371. **PMID: 28669342 [Impact Factor: 2.72]**
43. Hoseinzadeh E, Taha P, Chiang Wei C, Godini H, **Ashraf GM**, Taghavi M, Miri M. The impact of air pollutants, UV exposure and geographic location on vitamin D

- deficiency. **Food and Chemical Toxicology** (2018) 113:241-254. **PMID:** 29409825 [**Impact Factor:** 3.775]
44. Baez-Jurado E, Hidalgo-Lanussa O, Guio-Vega G, **Ashraf GM**, Echeverria V, Aliev G, Barreto GE. Conditioned medium of human adipose mesenchymal stem cells increases wound closure and protects human astrocytes following scratch assay in vitro. **Molecular Neurobiology** (2018) 55:5377-5392. **PMID:** 28936798 [**Impact Factor:** 4.586]
45. Sheikh IA, Jiffri EH, **Ashraf GM**, Kamal MA, Beg MA. Structural studies on inhibitory mechanisms of antibiotic, corticosteroid and catecholamine molecules on lactoperoxidase. **Life Sciences** (2018) 207:412-419. **PMID:** 29953881 [**Impact Factor:** 3.448]
46. **Ashraf GM***, Mahmoud MM, Tabrez S. Studies on immunological and degranulation properties of a galectin-1 purified from goat (*Capra hircus*) heart. **International Journal of Biological Macromolecules** (2018) 118:1183-1188. **PMID:** 29578020 [**Impact Factor:** 6.953]
47. Chuo SC, Abd-Talib N, Mohd-Setapar SH, Hassan H, Nasir HM, Ahmad A, Lokhat D, **Ashraf GM***. Reverse micelle extraction of antibiotics using an eco-friendly Sophorolipids biosurfactant. **Scientific Reports** (2018) 8:477. **PMID:** 29323139 [**Impact Factor:** 4.011]
48. Sirisha GVD, Rachel KV, Zaveri K, Yarla NS, Kiranmayi P, Ganash M, Alkreathy HM, Rajeh N, **Ashraf GM***. Molecular docking and *in vitro* studies of soap nut trypsin inhibitor (SNTI) against phospholipase A₂ isoforms in therapeutic intervention of inflammatory diseases. **International Journal of Biological Macromolecules** (2018) 114:556-564. **PMID:** 29578020 [**Impact Factor:** 6.953]
49. Tabrez S, **Ashraf GM**, Hindawi S. A putative association of interleukin-1 β promoter polymorphisms and its level in Saudi diabetic patients. **Critical Reviews™ in Eukaryotic Gene Expression** (2018) 28(4):349-356. **PMID:** [Impact Factor: 1.841]
50. Areiza-Mazo N, Robles J, Zamudio-Rodriguez JA, Giraldez L, Echeverria V, Barrera-Bailon B, Aliev G, Sahebkar A, **Ashraf GM**, Barreto GE. Extracts of *Physalis peruviana* protect astrocytic cells under oxidative stress with rotenone. **Frontiers in Chemistry** (2018) 6:276. **PMID:** 30175092 [**Impact Factor:** 4.155]
51. Zaidi SK, Ansari SA, Tabrez S, Hoda MN, **Ashraf GM**, Khan MS, Alnohair SF, Banu N. Garlic extract attenuates immobilization stress-induced alterations in plasma antioxidant/oxidant parameters and hepatic function in rats. **Chinese Journal of Integrative Medicines** (2017) 1-7. **PMID:** 28197933 [**Impact Factor:** 1.445]
52. Pirsahab M, Shahmoradi B, Beikmohammadi M, Azizi E, Hossini H, **Ashraf GM***. Photocatalytic degradation of Aniline from aqueous solutions under sunlight illumination using immobilized Cr:ZnO nanoparticles. **Scientific Reports**, (2017) 7:1473. **PMID:** 28469186 [**Impact Factor:** 4.011]
53. Bilal N, Suhail N, Hasan S, **Ashraf GM**, Fatima S, Khan HY, Alharbi MS, Alexiou A, Banu N. Exacerbation of N-nitrosodiethylamine induced hepatotoxicity and DNA damage in mice exposed to chronic unpredictable stress. **Frontiers in Pharmacology** (2017) 8:360. **PMID:** 28663731 [**Impact Factor:** 4.225]
54. Ibrahim GPS, Isloor A, Inamuddin, Asiri AM, Ismail N, Ismail AF, **Ashraf GM***. Novel, one-step synthesis of zwitterionic polymer nanoparticles via distillation-

- precipitation polymerization and its application for dye removal membrane. **Scientific Reports (2017)** 7:15889. PMID: 29162869 [Impact Factor: 4.011]
55. Sheikh IA, Jiffri EH, Kamal MA, **Ashraf GM**, Beg MA. Lactoperoxidase, an antimicrobial milk protein, as a potential activator of carcinogenic heterocyclic amines in breast cancer. **Anticancer Research (2017)** 37(11):6415-6420. PMID: 29061827 [Impact Factor: 1.935]
56. Pirsaeheb M, Hossini H, Secula MS, Parvaneh M, **Ashraf GM***. Application of high rate integrated anaerobic-aerobic/biogranular activated carbon sequencing batch reactor (IAnA-BioGACsBR) for treating strong municipal landfill leachate. **Scientific Reports (2017)** 7: 3109. PMID: 28596598 [Impact Factor: 4.011]
57. Rayavarapu S, Yarla NS, Kadiri SK, Bishayee A, Vidavalur S, Tadikonda R, Basha M, Pidugu VR, Dowluru KSVGK, Lakappa DB, Kamal MA, **Ashraf GM**, Tarasov VV, Chubarev VN, Klochkov SG, Barreto GE, Bachurin SO, Aliev G. Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities. **Scientific Reports (2017)** 7:8309. PMID: 28814788 [Impact Factor: 4.011]
58. Haque SU, Inamuddin, Nasar A, Rajender B, Khan A, Asiri AM, **Ashraf GM***. Optimization of glucose powered biofuel cell anode developed by polyaniline-silver as electron transfer enhancer and ferritin as biocompatible redox mediator. **Scientific Reports (2017)** 7:12703. PMID: 28983079 [Impact Factor: 4.011]
59. Tabrez S, Ali M, Jabir NR, Firoz CK, **Ashraf GM**, Hindawi S, Damanhour GA, Alama N. A putative association of interleukin-10 promoter polymorphisms with cardiovascular disease. **IUBMB Life (2017)** 69(7):522-527. PMID: 28474494 [Impact Factor: 3.051]
60. Zia Q, Azhar A, Ahmad S, Afsar M, Hasan Z, Owais M, Alam M, Akbar S, Ganash M, **Ashraf GM**, Zubair S, Aliev G. PeMtb: a database of MHC antigenic peptide of Mycobacterium tuberculosis. **Current Pharmaceutical Biotechnology (2017)** 18(8):648-652. PMID: 28914198 [Impact Factor: 1.516]
61. Perveen R, Inamuddin, Haque SU, Nasar A, Asiri AM, **Ashraf GM***. Electrocatalytic performance of chemically synthesized PIn-Au-SGO composite toward mediated biofuel cell anode. **Scientific Reports (2017)** 7:13353. PMID: 29042654 [Impact Factor: 4.011]
62. Hasan S, Suhail N, Bilal, N., **Ashraf, GM**, Zaidi SK, AlNohair S, Banu N. Chronic unpredictable stress deteriorates the chemopreventive efficacy of pomegranate through oxidative stress pathway. **Tumor Biology, (2016)** 37:5999-6006. PMID: 26596837 [Impact Factor: 3.650]
63. Al-Shabib NA, Husain FM, Ahmad F, Khan RA, Ahmad I, Alsharaeh E, Khan MS, Hussain A, Rehman MT, Yusuf M, Hassan I, Khan JM, **Ashraf GM**, Alsalme A, Al-Ajmi MF, Tarasov VV, Aliev G. Biogenic synthesis of Zinc oxide nanostructures from *Nigella sativa* seed: Prospective role as food packaging material inhibiting broad-spectrum quorum sensing. **Scientific Reports, (2016)** 6:36761. PMID: 27917856 [Impact Factor: 4.011]
64. Perveen A, Barreto GE, Jahan N, Wadud A, Alam MT, **Ashraf GM**, Aliev G. Antifertility activity of Lac (*Laccifer lacca* Kerr.) in female Wistar rat model. **Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry, (2016)** 16(1):39-48. PMID: NA [Impact Factor: NA]

65. Khan MF, Ansari AH, Hameedullah M, Ahmad E, Husain FM, Zia Q, Baig U, Zaheer MR, Alam MM, Khan AM, AlOthman ZA, Ahmad I, **Ashraf GM***, Aliev G. Sol-gel synthesis of thorn-like ZnO nanoparticles endorsing mechanical stirring effect and their antimicrobial activities: Potential role as nano-antibiotics. **Scientific Reports**, (2016) 6:27689. PMID: 27349836 [Impact Factor: 4.011]
66. Tanveer S, Banu S, Jabir NR, Khan MS, **Ashraf GM**, Manjunath NC, Tabrez S. Clinical and angiographic correlation of high-sensitivity C-reactive protein with acute ST elevation myocardial infarction (STEMI). **Experimental and Therapeutic Medicine**, (2016) 12:4089-4098. PMID: 28105138 [Impact Factor: 1.448]
67. Perveen A, Khan HY, Hadi SM, Damanhoury GA, Alharrasi A, Tabrez S, **Ashraf GM***. Pro-oxidant DNA breakage induced by the interaction of L-DOPA with Cu(II): a putative mechanism of neurotoxicity. **Advances in Experimental Medicine and Biology** (2015) 822:37-51. PMID: 25416975 [Impact Factor: 2.126]
68. Torrente D, Cabezas R, Avila M, Sanchez Y, Morales L, **Ashraf GM**, Barreto GE, Gonzalez J, Aliev G. Mechanisms of PDGFRalpha promiscuity and PDGFRbeta specificity in association with PDGFB. **Frontiers in Bioscience (Elite Ed.)** (2015) 7:434-446. PMID: 25961423 [Impact Factor:]
69. Zaidi SK, Ansari SA, **Ashraf GM**, Jafri MA, Tabrez S, Banu N. Reno-protective effect of garlic extract against immobilization stress induced changes in rats. **Asian Pacific Journal of Tropical Medicine** (2015) 5(5):364-369. PMID: [Impact Factor: 1.772]
70. **Ashraf GM***, Perveen A, Tabrez S, Zaidi SK, Kamal MA, Banu N. Studies on the role of goat heart galectin-1 as a tool for detecting post-malignant changes in glycosylation pattern. **Saudi Journal of Biological Sciences** (2015) 22(1):85-89. PMID: 25561889 [Impact Factor: 2.820]
71. Solís-Herrera A, **Ashraf GM**, del C A Esparza M, Arias RI, Bachurin SO, Barreto GE, Aliev G. Biological activities of QIAP1 as a melanin precursor and its therapeutic effects in wistar rats exposed to arsenic poisoning. **Central Nervous System Agents in Medicinal Chemistry** (2015) 15(2):99-108. PMID: 25909193 [Impact Factor:]
72. **Ashraf GM***, Perveen A, Tabrez S, Jabir NR, Damanhoury GA, Zaidi SK, Banu N. Altered galectin glycosylation: potential factor for the diagnostics and therapeutics of various cardiovascular and neurological disorders. **Advances in Experimental Medicine and Biology** (2015) 822:67-84. PMID: 25416978 [Impact Factor: 2.126]
73. Suhail N, Bilal N, Hasan S, Ahmad A, **Ashraf GM**, Banu N. Chronic unpredictable stress (CUS) enhances the carcinogenic potential of 7, 12-dimethylbenz(a)anthracene (DMBA) and accelerates the onset of tumor development in Swiss albino mice. **Cell Stress and Chaperones** (2015) 20(6):1023-36. PMID: 26272695 [Impact Factor: 2.903]
74. **Ashraf GM***, Perveen A, Zaidi SK, Tabrez S, Kamal MA, Banu, N. Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent. **Saudi Journal of Biological Sciences** (2015) 22(1):112-116. PMID: 25561893 [Impact Factor: 2.820]
75. Banu S, Jabir NR, Manjunath NC, Khan MS, **Ashraf GM**, Kamal MA, Tabrez S. Reduction of post-prandial hyperglycemia by mulberry tea in type-2 diabetes patients. **Saudi Journal of Biological Sciences** (2015) 22(1):32-36. PMID: 25561880 [Impact Factor: 2.820]

76. Kaminsky YG, Reddy VP, **Ashraf GM**, Ahmad A, Benberin VV, Kosenko EA, Aliev G. Age-related defects in erythrocyte 2,3-diphosphoglycerate metabolism in dementia. **Aging and Disease** (2013) 4(5):244-255. **PMID: 24124630 [Impact Factor: 5.058]**
77. Ahmad A, Rasheed N, Gupta P, Singh S, Siripurapu KB, **Ashraf GM**, Kumar R, Chand K, Maurya R, Banu N, Al-Sheeha M, Palit G. Novel Ocimumoside A and B as anti-stress agents: modulation of brain monoamines and antioxidant systems in chronic unpredictable stress model in rats. **Phytomedicine** (2012) 19(7):639-647. **PMID: 22455995 [Impact Factor: 4.180]**
78. Ahmad A, Rasheed N, **Ashraf GM**, Kumar R, Banu N, Khan F, Al-Sheeha M, Palit G. Brain region specific monoamine and oxidative changes during restraint stress. **Canadian Journal of Neurological Sciences** (2012) 39(3):311-318. **PMID: 22547510 [Impact Factor: 2.286]**
79. **Ashraf GM**, Banu N, Ahmad A, Singh LP, Kumar R. Purification, characterization, sequencing and biological chemistry of galectin-1 purified from *Capra hircus* (goat) heart. **The Protein Journal** (2011) 30(1):39-51. **PMID: 21210196 [Impact Factor: 1.029]**
80. Kumar R, Sharma A, Varadwaj P, Ahmad A, **Ashraf GM**. Classification of oral bioavailability of drugs by machine learning approaches: A comparative study. **Journal of Computational Interdisciplinary Sciences** (2011) 2(3):1-18. **PMID: NA [Impact Factor: 0.91]**
81. Hasan S, Bilal N, Naqvi S, **Ashraf GM**, Suhail N, Sharma S, Banu N. Multivitamin mineral and vitamins (E + C) supplementation modulate chronic unpredictable stress-induced oxidative damage in brain and heart of mice. **Biological Trace Element Research** (2011) 142(3):589-597. **PMID: 20635159 [Impact Factor: 2.431]**
82. Sharma A, Kumar R, Varadwaj PK, Ahmad A, **Ashraf GM**. A comparative study of support vector machine, artificial neural network and bayesian classifier for mutagenicity prediction. **Interdisciplinary Sciences: Computational Life Sciences** (2011) 3(3):232-239. **PMID: 21956745 [Impact Factor: 1.418]**
83. **Ashraf GM**, Bilal N, Suhail N, Hasan S, Banu N. Glycosylation of purified buffalo heart galectin-1 plays crucial role in maintaining its structural and functional integrity. **Biochemistry Moscow** (2010) 75(12):1450-1457. **PMID: 21314615 [Impact Factor: 1.886]**
84. **Ashraf GM**, Rizvi S, Naqvi S, Suhail N, Bilal N, Hasan S, Tabish M, Banu N. Purification, characterization, structural analysis and protein chemistry of a buffalo heart galectin-1. **Amino Acids** (2010) 39(5):1321-1332. **PMID: 17207926 [Impact Factor: 2.520]**

Review articles:

85. Bhardwaj S, Kesari KK, Rachamalla M, Mani S, **Ashraf GM**, Jha SK, Kumar P, Ambasta RK, Dureja H, Devkota HP, Gupta G, Chellappan DK, Singh SK, Dua K, Ruokolainen J, Kamal MA, Ojha S, Jha NK. CRISPR/Cas9 gene editing: new hope for Alzheimer's disease therapeutics. **Journal of Advanced Research** (2021) (Accepted, in press). **PMID: [Impact Factor: 10.479]**
86. Uddin MS, Mamun AA, Rahman MM, Jeandet P, Alexiou A, Behl T, Sarwar MS, Sobarzo-Sánchez E, **Ashraf GM**, Sayed AA, Albadrani GM, Peluso I, Abdel-Daim MM. Natural products for neurodegeneration: regulating neurotrophic signals. **Oxidative**

- Medicine and Cellular Longevity (2021) 8820406. PMID: 34239696 [Impact Factor: 6.543]**
87. Uddin MS, Kabir MT, Jalouli M, Rahman MA, Jeandet P, Behl T, Alexiou A, Albadrani GM, Abdel-Daim MM, Perveen A, **Ashraf GM**. Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease. **Current Neuropharmacology (2021) (Accepted, in press). PMID: 34525932 [Impact Factor: 7.363]**
88. Begum R, Howlader S, Mamun-Or-Rashid ANM, Rafiquzzaman SM, Ashraf GM, Albadrani GM, Sayed AA, Peluso I, Abdel-Daim MM, Uddin MS. Antioxidant and signal-modulating effects of brown seaweed-derived compounds against oxidative stress-associated pathology. **Oxidative Medicine and Cellular Longevity (2021) 9974890. PMID: 34336128 [Impact Factor: 6.543]**
89. Danish F, Khan MA, **Ashraf GM**, Bilgrami AL, Rizvi MMA. New horizons in the treatment of neurological disorders with tailorable gold nanoparticles. **Current Drug Metabolism (2021) (Accepted, in press). PMID: 34036910 [Impact Factor: 3.731]**
90. Rai SN, Singh P, Steinbusch HWM, Vamanu E, **Ashraf GM***, Singh MP. The role of vitamins in neurodegenerative disease: An Update. **Biomedicines (2021) 9(10):1284. PMID: 17207926 [Impact Factor: 6.081]**
91. Masoud AT, Hasan MT, Sayed A, Edward HN, Amer AM, Naga AE, Elfil M, Alghamdi BS, Perveen A, Ashraf GM, Bahbah EI. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. **Journal of the Neurological Sciences (2021) 427:117505. PMID: 34082147 [Impact Factor: 3.181]**
92. Yadav A, Pandey D, **Ashraf GM**, Rachana D. Peptide based therapy for neurological disorders. **Current Protein and Peptide Science (2021) (Accepted, in press). PMID: 34544337 [Impact Factor: 3.272]**
93. Walia V, Kaushik D, Mittal V, Kumar K, Verma R, Parashar J, Akter R, Rahman MH, Bhatia S, Al-Harrasi A, Karthika C, Bhattacharya T, Chopra H, **Ashraf GM**. Delineation of neuroprotective effects and possible benefits of antioxidants therapy for the treatment of Alzheimer's diseases by targeting mitochondrial-derived reactive oxygen species: bench to bedside. **Molecular Neurobiology (2021) 58(1):1-20. PMID: [Impact Factor: 4.586]**
94. Singh S, Sharma N, Behl T, Sarkar BC, Saha HR, Garg K, Singh SK, Arora S, Amran MS, Abdellatif AAH, Bilgrami AL, **Ashraf GM**, Rahman SM. Promising strategies of colloidal drug delivery-based approaches in psoriasis management. **Pharmaceutics (2021) (Accepted, in press). PMID: [Impact Factor: 6.321]**
95. Noor S, Mohammad T, **Ashraf GM**, Farhat J, Bilgrami AL, Eapen MS, Sohal SS, Yadav DK, Hassan MI. Mechanistic insights into the role of serum-glucocorticoid kinase 1 in diabetic nephropathy: A systematic review. **International Journal of Biological Macromolecules (2021) 193(A):562-573. PMID: 34715204. [Impact Factor: 6.953]**
96. Uddin MS, Sumsuzzman DM, Jeandet P, Behl T, Rauf A, Amran MS, **Ashraf GM**. Deciphering the interacting mechanisms of circadian disruption and Alzheimer's disease. **Neurochemical Research (2021) (Accepted, in press). PMID: [Impact Factor: 3.038]**
97. Rahman MS, Uddin MS, Rahman MA, Samsuzzaman M, Ahmed M, Behl T, Mathew B, Rauf A, Hafeez A, Perveen A, Barreto GE, **Ashraf GM**. Exploring the role of

- monoamine oxidase activity in aging and Alzheimer's disease. **Current Pharmaceutical Design (2021) (Accepted, in press). PMID: [Impact Factor: 3.116]**
98. Louka AM, Tsagkaris C, Christoforou P, Alexiou F, Simou P, Haranas I, Gkigkitzis I, Zouganelis G, Jha NK, Uddin MS, **Ashraf GM**, Shen B, Kamal MA, Alexiou A. Current trends of computational tools in geriatric medicine and frailty management. **Journal of Integrative Neuroscience (2021) (Accepted, in press). PMID: [Impact Factor: 2.117]**
99. Ahmad F, Haque S, Chavda V, **Ashraf GM***. Recent advances in synaptosomal proteomics in Alzheimer's disease. **Current Protein and Peptide Science (2021) (Accepted, in press). PMID: [Impact Factor: 3.272]**
100. Rahman MM, Ferdous KS, Ahmed MA, Islam MT, Khan MR, Perveen A, **Ashraf GM**, Uddin MS. Hutchinson-Gilford progeria syndrome: an overview of the molecular mechanism, pathophysiology and therapeutic approach. **Current Gene Therapy (2021) (Accepted, in press). PMID: 33655857 [Impact Factor: 2.431]**
101. Uddin MS, Kabir MT, Behl T, **Ashraf GM**. Reconsidering and reforming the amyloid cascade hypothesis. **Current Protein and Peptide Science (2021) (Accepted, in press). PMID: 33749562 [Impact Factor: 3.272]**
102. Uddin MS, Katha UT, **Ashraf GM***. Impaired quality control of mitochondria underlying the pathogenesis of Alzheimer's disease. **Current Drug Targets (2021) (Accepted, in press). PMID: 33687894 [Impact Factor: 2.632]**
103. Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, **Ashraf GM***. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. **Seminars in Cancer Biology (2021) (Accepted, in press). PMID: 33370605 [Impact Factor: 15.707]**
104. Kabir MT, Uddin MS, Zaman S, Rahman MS, Behl T, Ahmad A, Hafeez A, Perveen A, **Ashraf GM***. Exploring the anti-neuroinflammatory potential of steroid and terpenoid-derived phytochemicals to combat Alzheimer's disease. **Current Pharmaceutical Design (2021) (Accepted, in press). PMID: 33463452 [Impact Factor: 3.116]**
105. Makara-Studzińska MM, Somasundaram SG, Halicka J, Madej A, Leszek J, Rehan M, **Ashraf GM**, Gavryushova LV, Nikolenko VN, Mikhaleva LM, Muresanu C, Kirkland CE, Avila-Rodriguez M, Aliev G. Suicide and suicide attempts in the elderly patients: an epidemiological analysis of risk factors and prevention. **Current Pharmaceutical Design (2021) (Accepted, in press). PMID: 33243131 [Impact Factor: 3.116]**
106. Moni MMR, Begum M, Uddin MS, **Ashraf GM***. Deciphering the role of nanoparticle-based treatment for Parkinson's disease. **Current Drug Metabolism (2021) 22(7):550-560. PMID: 33530903 [Impact Factor: 3.731]**
107. Kabir MT, Uddin MS, Zaman S, Rahman MS, Behl T, Ahmad A, **Ashraf GM**. Exploring the anti-neuroinflammatory potential of steroid and terpenoid-derived phytochemicals to combat Alzheimer's disease. **Current Pharmaceutical Design (2021) (Accepted, in press). PMID: 33463452 [Impact Factor: 3.116]**
108. Ullah N, Maaiden EE, Uddin MS, **Ashraf GM**. Synaptotagmin-1: a multi-functional protein that mediates vesicle docking, priming, and fusion. **Current Protein and Peptide Science (2021) (Accepted, in press). PMID: [Impact Factor: 3.272]**

109. Uddin MS, Mamun AA, **Ashraf GM***. Neurotoxic A β : linking extracellular and intracellular A β in Alzheimer's disease. **Current Protein and Peptide Science (2021) (Accepted, in press)**. PMID: 33480343 [Impact Factor: 3.272]
110. Uddin MS, MT, Begum MM, Islam MS, Behl T, **Ashraf GM**. Exploring the role of CLU in the pathogenesis of Alzheimer's disease. **Neurotoxicity Research (2021) (Accepted, in press)**. PMID: 32820456 [Impact Factor: 2.992]
111. Sharma A, Manchanda R, Pottoo FH, **Ashraf GM**. Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders. **Current Drug Metabolism (2021) 22(4):251-262**. PMID: 33234099 [Impact Factor: 3.731]
112. **Ashraf GM***, Ebada MA, Suhail M, Ali A, Uddin MS, Bilgrami AL, Perveen A, Husain A, Tarique M, Hafeez A, Alexiou A, Ahmad A, Kumar R, Banu N, Najda A, Sayed AA, Albadrani GM, Abdel-Daim MM, Peluso I, Barreto GE. Dissecting sex-related cognition between Alzheimer's disease and diabetes: from molecular mechanisms to potential therapeutic strategies. **Oxidative Medicine and Cellular Longevity (2021) 4572471**. PMID: 33747345 [Impact Factor: 6.543]
113. Uddin MS, Khan ZA, Sumsuzzman DM, Perveen A, **Ashraf GM***. Challenges of gene therapy for neurodegenerative disorders. **Current Gene Therapy (2021) 21(1):3-10**. PMID: 33153421 [Impact Factor: 2.431]
114. Benmelouka AY, Munir M, Sayed A, Attia MS, Ali MM, Negida A, Alghamdi BS, Kamal MA, Barreto GE, Ashraf GM, Meshref M, Bahbah EI. Neural stem cell-based therapies and glioblastoma management: current evidence and clinical challenges. **International Journal of Molecular Sciences (2021) 22(5):2258**. PMID: [Impact Factor: 4.556]
115. Brzecka A, Madetko N, Nikolenko VN, **Ashraf GM**, Ejma M, Leszek J, Daroszewski C, Sarul K, Mikhaleva LM, Somasundaram SG, Kirkland CE, Bachurin SO, Aliev G. Sleep disturbances and cognitive impairment in the course of type 2 diabetes - possible link. **Current Neuropharmacology (2021) 19(1):78-91** PMID: 32148197 [Impact Factor: 7.363]
116. Uddin MS, Hasana S, Ahmad J, Hossain MF, Rahman MM, Behl T, Rauf A, Ahmad A, Hafeez A, Perveen A, **Ashraf GM***. Anti-neuroinflammatory potential of polyphenols by inhibiting NF- κ B to halt Alzheimer's disease. **Current Pharmaceutical Design (2021) 27(3):402-414**. PMID: 33213314 [Impact Factor: 3.116]
117. Uddin MS, Kabir MT, Mamun AA, Behl T, Mansouri RA, Aloqbi AA, Perveen A, Hafeez A, **Ashraf GM***. Exploring potential of alkaloidal phytochemicals targeting neuroinflammatory signaling of Alzheimer's disease. **Current Pharmaceutical Design (2021) 27(3):357-366**. PMID: 32473620 [Impact Factor: 3.116]
118. Kabir MT, Uddin MS, Zaman S, Begum Y, **Ashraf GM**, Bin-Jumah MN, Bungau SG, Mousa SA, Abdel-Daim MM. Molecular mechanisms of metal toxicity in the pathogenesis of Alzheimer's disease. **Molecular Neurobiology (2021) 58(1):1-20**. PMID: 32889653 [Impact Factor: 4.586]
119. Uddin MS, Hasana S, Hossain MF, Islam MS, Behl T, Perveen A, Hafeez A, **Ashraf GM***. Molecular genetics of early- and late-onset Alzheimer's disease. **Current Gene Therapy (2021) 21(1):43-52**. PMID: 33231156 [Impact Factor: 2.431]
120. Uddin MS, Motiar Rahman MM, Sufian MA, **Ashraf GM**, El-Seedi HR, Bin-Jumah MN, Mousa SA, Abdel-Daim MM. Exploring the new horizon of AdipoQ in obesity-

- related Alzheimer's dementia. **Frontiers in Physiology** (2021) 11:567678. **PMID: [Impact Factor: 3.367]**
121. Uddin MS, Mamun AA, Kabir MT, **Ashraf GM**, Bin-Jumah MN, Abdel-Daim MM. Multi-target drug candidates for multifactorial Alzheimer's disease: AChE and NMDAR as molecular targets. **Molecular Neurobiology** (2021) 58(1):281-303. **PMID: 32935230 [Impact Factor: 4.586]**
122. Uddin MS, Hasana S, Ahmad J, Hossain MF, Rahman MM, Behl T, Rauf A, Ahmad A, Hafeez A, Perveen A, **Ashraf GM**. Anti-neuroinflammatory potential of polyphenols by inhibiting NF- κ B to halt Alzheimer's disease. **Current Pharmaceutical Design** (2020) 27(3):402-414. **PMID: 33213314 [Impact Factor: 3.116]**
123. Narayanan SE, Rehman NA, Harilal S, Vincent A, Rajamma RG, Behl T, Uddin MS, **Ashraf GM**, Mathew B. Molecular mechanism of zinc neurotoxicity in Alzheimer's disease. **Environmental Science and Pollution Research** (2020) 27(35):43542-43552. **PMID: 32909132 [Impact Factor: 3.056]**
124. Uddin MS, Kabir MT, Tewari D, Mamun AA, Barreto GE, Bungau SG, Bin-Jumah MN, Abdel-Daim MM, **Ashraf GM***. Emerging therapeutic promise of ketogenic diet to attenuate neuropathological alterations in Alzheimer's disease. **Molecular Neurobiology** (2020) 57(12):4961-4977. **PMID: 32820459 [Impact Factor: 5.59]**
125. Mamun AA, Rahman MM, Zaman S, Munira MS, Uddin MS, Rauf A, Banu N, **Ashraf GM***. Molecular insight into the crosstalk of UPS components and Alzheimer's disease. **Current Protein and Peptide Science** (2020) 21(12):1193-1201. **PMID: 32964822 [Impact Factor: 3.272]**
126. Kabir MT, Uddin MS, Setu JR, **Ashraf GM**, Bin-Jumah MN, Abdel-Daim MM. Exploring the role of PSEN mutations in the pathogenesis of Alzheimer's disease. **Neurotoxicity Research** (2020) 38(4):833-849. **PMID: 32556937 [Impact Factor: 2.992]**
127. Uddin MS, Rahman MA, Kabir MT, Behl T, Mathew B, Perveen A, Barreto GE, Bin-Jumah MN, Abdel-Daim MM, **Ashraf GM***. Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease. **IUBMB Life** (2020) 72(9):1843-1855. **PMID: 32472959 [Impact Factor: 3.051]**
128. Uddin MS, Kabir MT, Jakaria M, Sobarzo-Sánchez E, Barreto GE, Perveen A, Hafeez A, Bin-Jumah MN, Abdel-Daim MM, **Ashraf GM***. Exploring the potential of neuroproteomics in Alzheimer's disease. **Current Topics in Medicinal Chemistry** (2020) 20(25):2263-2278. **PMID: 32493192 [Impact Factor: 3.218]**
129. Kabir MT, Uddin MS, Abdeen A, **Ashraf GM**, Perveen A, Hafeez A, Bin-Jumah MN, Abdel-Daim MM. Evidence linking protein misfolding to quality control in progressive neurodegenerative diseases. **Current Topics in Medicinal Chemistry** (2020) 20(23):2025-2043. **PMID: 32552649 [Impact Factor: 3.218]**
130. Uddin MS, Mamun AA, Rahman MA, Behl T, Perveen A, Hafeez A, Bin-Jumah MN, Abdel-Daim MM, **Ashraf GM***. Emerging proof of protein misfolding and interactions in multifactorial Alzheimer's disease. **Current Topics in Medicinal Chemistry** (2020) 20(26):2380-2390. **PMID: 32479244 [Impact Factor: 3.218]**
131. Uddin MS, Kabir MT, Rahman MH, Alim MA, Rahman MM, Khatkar A, Mamun AA, Rauf A, Mathew B, **Ashraf GM**. Exploring the multifunctional neuroprotective promise of rasagiline derivatives for multi-dysfunctional Alzheimer's disease. **Current**

- Pharmaceutical Design (2020) 26(37):4690-4698. PMID: 32250219 [Impact Factor: 2.142]**
132. Sayed A, Bahbah EI, Kamel S, Barreto GE, **Ashraf GM***, Elfil M. The neutrophil-to-lymphocyte ratio in Alzheimer's disease: current understanding and potential applications. **Journal of Neuroimmunology (2020) 349:577398. PMID: [Impact Factor: 3.125]**
133. Uddin MS, Mamun AA, Kabir MT, Ahmad J, Jeandet P, Md. Sarwar MS, **Ashraf GM**, Aleya L. Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration. **European Journal of Pharmacology (2020) 173412. PMID: 32771668 [Impact Factor: 3.263]**
134. Kabir MT, Uddin MS, Hossain MF, Abdulhakim JA, Alam MA, **Ashraf GM**, Bungau SG, Bin-Jumah MN, Abdel-Daim MM, Aleya L. nCOVID-19 pandemic: from molecular pathogenesis to potential investigational therapeutics. **Frontiers in Cell and Developmental Biology (2020) 10; 8:616. PMID: 32754599 [Impact Factor: 5.026]**
135. Uddin MS, Kabir MT, Tewari D, Mamun AA, Mathew B, Aleya L, Barreto GE, Bin-Jumah MN, Abdel-Daim MM, **Ashraf GM***. Revisiting the role of brain and peripheral A β in the pathogenesis of Alzheimer's disease. **Journal of the Neurological Sciences (2020) 416:116974. PMID: 32559516 [Impact Factor: 2.651]**
136. Uddin MS, Tewari D, Sharma G, Kabir MT, Barreto GE, Bin-Jumah MN, Perveen A, Abdel-Daim MM, **Ashraf GM***. Molecular mechanisms of ER stress and UPR in the pathogenesis of Alzheimer's disease. **Molecular Neurobiology (2020) 57(7):2902-2919. PMID: 32430843 [Impact Factor: 4.586]**
137. Mamun AA, Uddin MS, Bashir MFB, Zaman S, Begum Y, Bulbul IJ, Islam MS, Sarwar MS, Mathew B, Amran MS, **Ashraf GM**, Bin-Jumah MN, Mousa SA, Abdel-Daim MM. Molecular insight into the therapeutic promise of targeting APOE4 for Alzheimer's disease. **Oxidative Medicine and Cellular Longevity (2020) 5086250. PMID: 32509144 [Impact Factor: 5.076]**
138. Uddin MS, Mamun AA, Rahman MA, Kabir MT, Alkahtani S, Alanazi IS, Perveen A, **Ashraf GM**, Bin-Jumah MN, Abdel-Daim MM. Exploring the promise of flavonoids to combat neuropathic pain: from molecular mechanisms to therapeutic implications. **Frontiers in Neuroscience (2020) 14:478. PMID: 32587501 [Impact Factor: 3.566]**
139. Saeed M, Faisal SM, Akhtar F, Ahmad S, Alreshidi MM, Kausar MA, Kazmi S, Saeed A, Adnan M, **Ashraf GM***. Human papillomavirus induced cervical and oropharyngeal cancers: from mechanisms to potential immuno-therapeutic strategies. **Current Drug Metabolism (2020) 21(3):167-177. PMID: 32316888 [Impact Factor: 3.731]**
140. Uddin S, Kabir T, Rahman M, Mathew B, Shah MA, **Ashraf GM**. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology. **Journal of Pharmacy and Pharmacology (2020) 72(8):1001-1012. PMID: 32149402 [Impact Factor: 2.39]**
141. Uddin MS, Kabir MT, Rahman MS, Behl T, Jeandet P, **Ashraf GM**, Najda A, Bin-Jumah MN, El-Seedi HR, Abdel-Daim MM. Revisiting the amyloid cascade hypothesis: from anti-A β therapeutics to auspicious new ways for Alzheimer's disease. **International Journal of Molecular Sciences (2020) 21(16): 5858. PMID: [Impact Factor: 4.183]**

142. Uddin MS, Mamun AA, Sumsuzzman DM, **Ashraf GM**, Perveen A, Bungau SG, Mousa SA, El-Seedi HR, Bin-Jumah MN, Abdel-Daim MM. Emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in Alzheimer's disease. **Frontiers in Pharmacology (2020)** 11:1097. **PMID: 32792944 [Impact Factor: 4.225]**
143. Makkar R, Behl T, Bungau S, Zengin G, Mehta V, Kumar A, Uddin S, **Ashraf GM**, Abdel-Daim MM, Arora S, Oancea R. Nutraceuticals in neurological disorders. **International Journal of Molecular Sciences (2020)** 21(12):4424. **PMID: 32580329 [Impact Factor: 4.183]**
144. Kabir MT, Uddin MS, Mathew B, Das PK, Perveen A, **Ashraf GM***. Emerging promise of immunotherapy for Alzheimer's disease: a new hope for the development of Alzheimer's vaccine. **Current Topics in Medicinal Chemistry (2020)** 20(13):1214-1234. **PMID: 32321405 [Impact Factor: 3.218]**
145. Uddin MS, Kabir MT, Mamun AA, Barreto GE, Rashid M, Perveen A, **Ashraf GM***. Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease. **International Immunopharmacology (2020)** 27;84:106479. **PMID: 32353686 [Impact Factor: 3.361]**
146. Uddin MS, Kabir MT, Mathew B, Jeandet P, **Ashraf GM**, Perveen A, Bin-Jumah MN, Mousa SA, Abdel-Daim MM. Novel anti-Alzheimer's therapeutic molecules targeting amyloid precursor protein processing. **Oxidative Medicine and Cellular Longevity (2020)** 29;2020:7039138. **PMID: 32411333 [Impact Factor: 5.076]**
147. Uddin MS, Hossain MF Mamun AA, Shah MA Hasana S Bulbul IS, Sarwar MS, Mansouri RA, **Ashraf GM**, Rauf A, Abdel-Daim MM, Bin-Jumah MN. Exploring the multimodal role of phytochemicals by modulating cellular signal pathways to combat age-related neurodegeneration. **Science of the Total Environment (2020)** 10(725):138313. **PMID: 32464743 [Impact Factor: 6.551]**
148. Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, **Ashraf GM**, Mathew B, Bin-Jumah MN, Abdel-Daim MM. Combination drug therapy for the management of Alzheimer's disease. **International Journal of Molecular Sciences (2020)** 5;21(9):E3272. **PMID: 32380758 [Impact Factor: 4.183]**
149. Uddin MS, Tewari D, Mamun AA, Kabir MT, Niaz K, Wahed MIW, Barreto GE, **Ashraf GM***. Circadian and sleep dysfunction in Alzheimer's disease. **Ageing Research Reviews (2020)** 60:101046. **PMID: 32171783 [Impact Factor: 10.895]**
150. Uddin MS, Kabir MT, Niaz K, Jeandet P, Clément C, Mathew B, Rauf A, Rengasamy K, Sobarzo-Sánchez E, Aleya L, **Ashraf GM**. Molecular insight into the therapeutic promise of flavonoids against Alzheimer's disease. **Molecules (2020)** 25(6):1267. **PMID: 32168835 [Impact Factor: 3.060]**
151. Al Mamun A, Uddin MS, Kabir MT, Khanum S, Sarwar MS, Mathew B, Rauf A, Ahmed M, **Ashraf GM**. Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer's disease. **Neurotoxicity Research (2020)** 38(1):8-17. **PMID: 32157628 [Impact Factor: 3.311]**
152. Pottoo FH, Sharma S, Javed MN, Barkat MA, Harshita, Alam MS, Naim MJ, Alam O, Ansari MA, Barreto GE, **Ashraf GM***. Lipid-based nanoformulations in the treatment of neurological disorders. **Drug Metabolism Reviews (2020)** 52(1):185-204. **PMID: 32116044 [Impact Factor: 4.702]**

153. Uddin MS, Rahman MM, Jakaria M, Rahman MS, Hossain MS, Islam A, Ahmed M, Mathew B, Omar UM, Barreto GE, **Ashraf GM***. Estrogen signaling in Alzheimer's disease: molecular insights and therapeutic targets for Alzheimer's dementia. **Molecular Neurobiology** (2020) 57(6):2654-2670. PMID: 32297302 [Impact Factor: 4.586]
154. Mamun AA, Uddin MS, Mathew B, **Ashraf GM***. Toxic tau: structural origins of tau aggregation in Alzheimer's disease. **Neural Regeneration Research** (2020) 15(8):1417-1420. PMID: 31997800 [Impact Factor: 5.135]
155. Alexiou A, Simou P, Alexiou F, Chatzichronis S, **Ashraf GM***. Social and ethical impact of advanced artificial and biological enhancements. **The Open Public Health Journal** (2020) 13:62-68. PMID: [Impact Factor:]
156. Hidalgo-Lanussa O, Baez-Jurado E, Echeverria V, **Ashraf GM**, Sahebkar A, Garcia-Segura LM, Melcangi RC, Barreto GE. Lipotoxicity, neuroinflammation, glial cells and estrogenic compounds. **Journal of Neuroendocrinology** (2020) 32(1): e12776. PMID: 31334878 [Impact Factor: 3.04]
157. Baig MH, Baker A, **Ashraf GM**, Dong JJ. ASK1 and its role in cardiovascular and other disorders: Available treatments and future prospects. **Expert Review of Proteomics** (2019) 16(10):857-870. PMID: 31593641 [Impact Factor: 2.963]
158. Kabir MT, Uddin MS, Begum MM, Thangapandiyam S, Rahman MS, Aleya L, Mathew B, Ahmed M, **Ashraf GM**, Barreto GE. Cholinesterase inhibitors for Alzheimer's disease: multitargeting strategy based on Anti-Alzheimer's drugs repositioning. **Current Pharmaceutical Design** (2019) 25(33):3519-3535. PMID: 31593530 [Impact Factor: 3.116]
159. Hossain MF, Uddin MS, Uddin GMS, Sumsuzzman DM, Islam MS, Barreto GE, Mathew B, **Ashraf GM***. Melatonin in Alzheimer's disease: a latent endogenous regulator of neurogenesis to mitigate Alzheimer's neuropathology. **Molecular Neurobiology** (2019) 56:8255-8276. PMID: 31209782 [Impact Factor: 4.586]
160. Kabir MT, Sufian MA, Uddin MS, Begum M, Akhter S, Islam A, Mathew B, Islam MS, Amran MS, **Ashraf GM***. NMDA Receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer's therapy. **Current Pharmaceutical Design** (2019) 25(33):3506-3518. PMID: 31604413 [Impact Factor: 3.116]
161. Baez-Jurado E, Hidalgo-Lanussa O, Barrera-Bailón B, **Ashraf GM**, Barreto GE. Secretome of mesenchymal stem cells and its potential effects on brain pathologies. **Molecular Neurobiology** (2019) 56(10) 6902-6927. PMID: 30941733 [Impact Factor: 4.586]
162. Tiwari P, Katyal A, Khan MF, **Ashraf GM*** Ahmad K. Lead optimization resources in drug discovery for diabetes. **Endocrine, Metabolic & Immune Disorders - Drug Targets** (2019) 19(6): 754-774. PMID: 30941733 [Impact Factor: 1.104]
163. Khan MA, Khurana N, Ahmed RS, Umar S, Sarwar AHMG, Alam Q, Kamal MA, **Ashraf GM***. Chemokines: a potential therapeutic target to suppress autoimmune arthritis. **Current Pharmaceutical Design** (2019) 25(27) 2937-2946. PMID: 31580792 [Impact Factor: 2.412]
164. Cabezas R, Baez-Jurado E, Hidalgo-Lanussa O, Moran VE, **Ashraf GM**, Sahebkar A, Barreto GE. Growth factors and neuroglobin in astrocytes protection against neurodegeneration and oxidative stress. **Molecular Neurobiology** (2019) 56(4):2339-2351. PMID: 29982985[Impact Factor: 4.586]

165. Uddin MS, Kabir MT, Jakaria M, Mamun AA, Niaz K, Amran MS, Barreto GE, **Ashraf GM***. Endothelial PPAR γ is crucial for averting age-related vascular dysfunction by stalling oxidative stress and ROCK. **Neurotoxicity Research** (2019) 36(2):437-438. PMID: 31055770 [Impact Factor: 3.311]
166. Ullah MF, Ahmad A, Bhat SH, Abu-Duhier FM, Barreto GE, **Ashraf GM***. Impact of sex differences and gender specificity on behavioral characteristics and pathophysiology of neurodegenerative disorders. **Neuroscience and Biobehavioral Reviews** (2019) 102:95-105. PMID: 30959072 [Impact Factor: 8.002]
167. Klochkov SG, Neganova ME, Yarla NS, Parvathanen M, Sharma B, Tarasov VV, Bachurin SO, **Ashraf GM**, Aliev G. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. **Seminars in Cancer Biology** (2019) 56:128-134. PMID: 29100957 [Impact Factor: 15.707]
168. Uddin MS, Kabir MT, Mamun AA, Abdel-Daim MM, Barreto GE, **Ashraf GM***. APOE and Alzheimer's disease: evidence mounts that targeting APOE4 may combat Alzheimer's pathogenesis. **Molecular Neurobiology** (2019) 56(4):2450-2465. PMID: 30032423 [Impact Factor: 4.586]
169. Shakil S, Baig MH, Tabrez S, Rizvi SMD, Zaidi SK, **Ashraf GM**, Ansari SA, Khan AAP, Al-Qahtani MH, Abuzenadah AM, Chaudhary AG. Molecular and enzinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy. **Seminars in Cancer Biology** (2019) 56:47-55. PMID: 29122685 [Impact Factor: 15.707]
170. Tarasov VVT, Chubarev VN, **Ashraf GM**, Dostdar SA, Sokolov AV, Melnikova TI, Sologova SS, Grigorevskich EM, Makhmutova A, Kinzirsky AS, Klochkov SG, Aliev G. How cancer cells resist chemotherapy: design and development of drugs targeting protein-protein interactions. **Current Topics in Medicinal Chemistry** (2019) 19(6):394-412. PMID: 30834839 [Impact Factor: 3.218]
171. Athanasios A, Stylianos C, Perveen A, Hafeez A, **Ashraf GM***. Algorithmic and stochastic representations of gene regulatory networks and protein-protein interactions. **Current Topics in Medicinal Chemistry** (2019) 19(6):413-425. PMID: 30854971 [Impact Factor: 3.218]
172. Khan MA, Alam Q, Haque A, Ashafaq M, Khan MJ, **Ashraf GM***, Ahmad M. Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer's disease: An update. **Current Neuropharmacology** (2019) 17(3):232-246. PMID: 30152284 [Impact Factor: 7.363]
173. Uddin MS, Mamun AA, Kabir MT, Jakaria M, Mathew B, Barreto GE, **Ashraf GM***. Nootropic and anti-Alzheimer's actions of medicinal plants: an insight into therapeutic potential to alleviate Alzheimer's neuropathology. **Molecular Neurobiology** (2019) 56(7):4925-4944. PMID: 30414087 [Impact Factor: 4.586]
174. Sharma AK, Sharma VR, Gupta GK, **Ashraf GM**, Kamal MA. Advanced glycation end products (AGEs), glutathione and breast cancer: factors, mechanism and therapeutic interventions. **Current Drug Metabolism** (2019) 20(1):65-70. PMID: 30207227 [Impact Factor: 3.731]
175. Baez-Juradoa E, Rincón-Benavidesa MA, Hidalgo-Lanussaa O, Guio-Vegaa G, **Ashraf GM**, Sahebkar A, Echeverria V, Garcia-Segura LM, Barreto GE. Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor

- Modulators in brain cells. **Frontiers in Neuroendocrinology** (2019) 52:44-64. PMID: 30223003 [Impact Factor: 7.852]
176. Makhdoumi P, Limoe M, **Ashraf GM***, Hossini H. Molecular mechanism of aniline induced spleen toxicity and neuron toxicity in experimental rat exposure: A review. **Current Neuroparmacology** (2019) 17(3):201-213. PMID: 30081786 [Impact Factor: 7.363]
177. Makara-Studzinska M, Madej A, Trypka E, Leszek J, Tarasov VV, **Ashraf GM**, Yarla NS, Aliev G. Quality of life and social support in women with urinary incontinence. **Current Women's Health Reviews**. (2019) 15(2):123-129. PMID: [Impact Factor:]
178. Aliev G, **Ashraf GM**, Tarasov VV, Chubarev VN, Leszek J, Gasiorowski K, Makhmutova A, Baesa S, Avila-Rodriguez M, Ustyugov A, Bachurin SO. Alzheimer disease- future therapy based on dendrimers. **Current Neuroparmacology** (2019) 17(3):288-294. PMID: 30227819 [Impact Factor: 7.363]
179. **Ashraf GM**, Tarasov VV, Makhmutova A, Chubarev VN, Avila-Rodriguez M, Bachurin SO, Aliev G. The possibility of an infectious etiology of Alzheimer disease. **Molecular Neurobiology** (2019) 56:4479-4491. PMID: 30338482 [Impact Factor: 4.586]
180. Uddin MS, Mamun AA, Labu ZK, Hidalgo-Lanussa O, Barreto GE, **Ashraf GM*** Autophagic dysfunction in Alzheimer's disease: cellular and molecular mechanistic approaches to halt Alzheimer's pathogenesis. **Journal of Cellular Physiology** (2019) 234:8094-8112. PMID: 30362531 [Impact Factor: 4.522]
181. Martin-Jiménez C, Gaitán-Vaca D, Areiza N, **Ashraf GM**, González J, Sahebkar A, Garcia-Segura LM, Barreto GE. Astrocytes mediate protective actions of estrogenic compounds after traumatic brain injury. **Neuroendocrinology** (2019) 108:142-160. PMID: 30391959 [Impact Factor: 6.804]
182. Alexiou A, Soursou G, Chatzichronis S, Gasparatos E, Kamal MA, Yarla NS, Perveen A, Barreto GE, **Ashraf GM***. Role of GTPases in the regulation of mitochondrial dynamics in Alzheimer's disease and CNS-related disorders. **Molecular Neurobiology** (2019) 56:4530-4538. PMID: 30338485 [Impact Factor: 4.586]
183. Chaudhary S, Islam Z, Mishra V, Rawat S, **Ashraf GM***, Kolatkar PR. Sox2: A regulatory factor in tumorigenesis and metastasis. **Current Protein & Peptide Science** (2018) 19(9):850-857. PMID: [Impact Factor: 3.272]
184. Islam Z, Nagampalli RSK, Fatima MT, **Ashraf GM***. New paradigm in ankyrin repeats: beyond protein-protein interaction module. **International Journal of Biological Macromolecules** (2018) 109:1164-1173. PMID: 28412342 [Impact Factor: 4.784]
185. Tarasov VV, Kudryashov NV, Chubarev VN, Kalinina TS, Barreto GE, **Ashraf GM**, Aliev G. Pharmacological aspects of neuro-immune interactions. **Current Pharmaceutical Design** (2018) 24(1):15-21. PMID: 28875850 [Impact Factor: 2.412]
186. Fazal SA, Khan M, Nishi SE, Alam F, Zarin N, Bari MT, **Ashraf GM***. A clinical update and global economic burden of rheumatoid arthritis. **Endocrine Metabolic & Immune Disorders-Drug Targets** (2018) 18(2):98-109. PMID: 29141572 [Impact Factor: 1.897]

187. Baig MH, Ahmad K, Saeed M, Alharbi AM, Barreto GE, **Ashraf GM**, Choi I. Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases. **Biomedicine & Pharmacotherapy (2018)** 103:574-581. **PMID:** 29677544 [**Impact Factor: 3.457**]
188. Hussain T, Bajpai S, Saeed M, Moin A, Alafnan A, Khan M, Kamal MA, Ganash M, **Ashraf GM***. Potentiating effect of ethnomedicinal plants against proliferation on different cancer cell lines. **Current Drug Metabolism (2018)** 19(7):584-595. **PMID:** 29512451 [**Impact Factor: 3.731**]
189. Sheikh IA, Yasir M, Khan I, Khan SB, Azum N, Jiffri EH, Kamal MA, **Ashraf GM**, Beg MA. Lactoperoxidase immobilization on silver nanoparticles enhances its antimicrobial activity. **Journal of Dairy Research (2018)** 85(4):460-464. **PMID:** 30136638 [**Impact Factor: 1.421**]
190. Sychev DA, **Ashraf GM**, Svistunov AA, Maksimov ML, Tarasov VV, Chubarev VN, Otdelenov VA, Denisenko NP, Barreto GE, Aliev G. The cytochrome CYP 450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. **Drug Design, Development and Therapy (2018)** 12:1147-1156. **PMID:** 29780235 [**Impact Factor: 2.822**]
191. Brzecka A, Leszek J, **Ashraf GM**, Ejma M, Ávila-Rodríguez MF, Yarla NS, Tarasov VV, Chubarev VN, Samsonova AN, Barreto GE, Aliev G. Sleep disorders associated with Alzheimer's disease: A perspective. **Frontiers in Neuroscience (2018)** 12:330 **PMID:** 29904334 [**Impact Factor: 3.566**]
192. Fernandez L, Bustos RH, Zapata CD, García JC, Jáuregui E, **Ashraf GM**. Immunogenicity in protein and peptide based-therapeutics: An overview. **Current Protein & Peptide Science (2018)** 19(10):958-971. **PMID:** 28847291 [**Impact Factor: 2.520**]
193. Rizvi SMD, Hussain T, Ahmed ABF, Alshammari TM, Moin A, Ahmed MQ, Barreto GE, Kamal MA, **Ashraf GM***. Gold nanoparticles: a plausible tool to combat neurological bacterial infections in humans. **Biomedicine & Pharmacotherapy (2018)** 107:7-18. **PMID:** 30075371 [**Impact Factor: 3.457**]
194. Azhar A[#], **Ashraf GM^{#,*}**, Zia Q, Ansari SA, Perveen A, Hafeez A, Saeed M, Kamal MA, Alexiou A, Ganash M, Yarla NS, Baesa SS, Alfiky MM, Bajouh OS. Frontier view on nanotechnological strategies for neuro-therapy. **Current Drug Metabolism (2018)** 19(7):596-604. **PMID:** 29512448 [**Impact Factor: 3.731**]
195. Volcho KP, Laev SS, **Ashraf GM**, Aliev G, Salakhutdinov NF. Application of monoterpenoids and their derivatives for treatment of neurodegenerative disorders. **Current Medicinal Chemistry (2018)** 25(39):5327-5346. **PMID:** 28079000 [**Impact Factor: 3.894**]
196. Alexiou A, Soursou G, Yarla NS, **Ashraf GM***. Proteins commonly linked to autism spectrum disorder and Alzheimer's disease. **Current Protein & Peptide Science (2018)** 19(9):876-880. **PMID:** 28901249 [**Impact Factor: 3.272**]
197. Fatima MT, Islam Z, Ahmad E, **Ashraf GM***. Ionic gradient liposomes: recent advances in the stable entrapment and prolonged released of local anaesthetics and anticancer drugs. **Biomedicine & Pharmacotherapy (2018)** 107:34-43. **PMID:** 30077836 [**Impact Factor: 3.457**]

198. Ustyugov A, Shevtsova E, Barreto GE, **Ashraf GM**, Bachurin SO, Aliev G. New therapeutic property of Dimebon as a neuroprotective agent. **Current Medicinal Chemistry** (2018) 25(39): 5315-5326. PMID: 27494393 [Impact Factor: 3.894]
199. Alexiou A, Nizami B, Khan FI, Soursou G, Vairaktarakis C, Chatzichronis S, Tsiamis V, Manztavinos V, Yarla NS, **Ashraf GM***. Mitochondrial dynamics and proteins related to neurodegenerative diseases. **Current Protein & Peptide Science** (2018) 19(9):850-857. PMID: 28799502 [Impact Factor: 3.272]
200. Saeed M, Alshammari FD, Alam MJ, Sarim KM, Ahmad K, Hussain T, Khan M, Kamal MA, **Ashraf GM***. A synopsis on the role of human papilloma virus infection in cervical cancer. **Current Drug Metabolism** (2018) 19(9):798-805. PMID: [Impact Factor: 3.731]
201. Khan MA, Alam K, **Ashraf GM**, Rizvi MA. Impact of hydroxyl radical modified-human serum albumin autoantigens in systemic lupus erythematosus. **Current Protein & Peptide Science** (2018) 19(9):881-888. PMID: 28745222 [Impact Factor: 3.272]
202. Herrera AS, **Ashraf GM**, Esparza MDCA, Tarasov VV, Avila-Rodriguez MF, Makhmutova A, Samsonova AN, Ganash M, Hafeez A, Bachurin SO, Aliev G. Cerebrospinal fluid, brain electrolytes balance, and the unsuspected intrinsic property of melanin to dissociate the water molecule. **CNS & Neurological Disorders - Drug Targets** (2018) 17(10):743-756. PMID: 30179148 [Impact Factor: 2.761]
203. Aziz ZAA, Ahmad A, Setapar SHM, Karakucuk A, Azim MM, Lokhat D, Rafatullah M, Ganash M, Kamal MA, **Ashraf GM***. Essential oils: extraction techniques, pharmaceutical and therapeutic potential- a review. **Current Drug Metabolism** (2018) 19(13):1100-1110. PMID: 30039757 [Impact Factor: 3.731]
204. Putta S, Yarla NS, Kumar KE, Lakkappa DB, Kamal MA, Scotti L, Scotti MT, **Ashraf GM**, Rao BSS, Kumari DS, Reddy GV, Tarasov VV, Imandi SB, Aliev G. Preventive and therapeutic potentials of anthocyanins in diabetes and associated complications. **Current Medicinal Chemistry** (2018) 25(39):5347-5371. PMID: 29210634 [Impact Factor: 3.894]
205. Ahmad K, Rabbani G, Baig MH, Lim JH, Khan ME, Lee EJ, **Ashraf GM***, Choi I. nanoparticle-based drugs: A potential armamentarium of effective anti-cancer therapies. **Current Drug Metabolism** (2018) 19(10):839-846. PMID: 28831911 [Impact Factor: 3.731]
206. Korada SK, Yarla NS, Mishra V, Daim MA, Sharma B, **Ashraf GM**, Reggi R, Palmery M, Peluso I, Kamal MA. Single probiotic versus multiple probiotics - a debate in current scenario for alleviating health benefits. **Current Pharmaceutical Design** (2018) 24(35):4150-4153. PMID: 30317991 [Impact Factor: 3.116]
207. **Ashraf GM***, Azhar A, Zia Q, Ali A, Rehan M, Owais M, Alexiou A, Rauf A, Ganash M, Kamal MA, Rajeh N. Relationship between CNS and Immunology: Correlation with Psychology. **Current Drug Metabolism** (2018) 19(10):847-855. PMID: 29380699 [Impact Factor: 3.731]
208. Leszek J, Trypka E, Koutsouraki E, Michmizos D, Yarla NS, **Ashraf GM**, Aliev G. Late-life depression and Alzheimer disease: a potential synergy of the underlying mechanisms. **Current Medicinal Chemistry** (2018) 25(39):5389-5394. PMID: 27593962 [Impact Factor: 3.894]
209. Jabir NR, Firoz CK, Khan MS, Zaidi SK, **Ashraf GM**, Shakil S, Kamal MA, Tabrez S. Potential linkage between cerebrovascular diseases and metabolic syndrome.

- Current Drug Metabolism, (2017) 18(1):62-68. PMID: 27515564 [Impact Factor: 3.731]**
210. Putta S, Yarla NS, Peluso I, Tiwari DK, Reddy GV, Giri PV, Kumar N, Malla R, Rachel V, Bramhachari PV, Reddy DRS, Bade R, Mannarapu M, Barreto GE, Lu DY, Tarasov VV, Chubarev VV, Ribeiro FF, Scotti L, Scotti MT, Kamal MA, **Ashraf GM**, Aliev G, Perry G, Sarker SD, Rao CV, Bishayee A. Anthocyanins: multi-target agents for prevention and therapy of chronic diseases. **Current Pharmaceutical Design (2017) 23(41):6321-6346. PMID: 28741457 [Impact Factor: 3.116]**
211. Ghotme KA, Barreto GE, Echeverria V, Gonzalez J, Bustos RH, Sanchez M, Leszek J, Yarla NS, Gómez RM, Tarasov VV, **Ashraf GM**, Aliev G. Gliomas: new perspectives in diagnosis, treatment and prognosis. **Current Topics in Medicinal Chemistry, (2017) 17(12):1438-1447. PMID: 28049399 [Impact Factor: 3.218]**
212. Azhar A, Ahmad E, Zia Q, Owais M, **Ashraf GM***. Recent updates on molecular genetic engineering approaches and applications of human therapeutic proteins. **Current Protein and Peptide Science, (2017) 18(3):217-232. PMID: 27587281 [Impact Factor: 2.520]**
213. Khan AAP, Khan A, Asiri AM, **Ashraf GM**, Alhogbia BG. Graphene oxide based metallic nanoparticles and their some biological and environmental application. **Current Drug Metabolism (2017) 18(11):1020-1029. PMID: 29034831 [Impact Factor: 2.277]**
214. Ansari SA, Satar R, Perveen A, **Ashraf GM***. Current opinion in Alzheimer's disease therapy by nanotechnology-based approaches. **Current Opinion in Psychiatry, (2017) 30(2):128-135. PMID: 28009724 [Impact Factor: 4.483]**
215. **Ashraf GM***, Perveen A, Zaidi SK, Ahmad A, Shakil S, Firoz CK, Jabir NR, Hassan I, Khan TA, Yarla NS, Tabrez S. Galectins- a potential target for cardiovascular therapy. **Current Vascular Pharmacology, (2017) 15:296-312. PMID: 28155611 [Impact Factor: 2.583]**
216. Athanasios A, Charalampos V, Vasileios T, **Ashraf GM***. Protein-protein interaction (PPI) network: Recent advances in drug discovery. **Current Drug Metabolism, (2017) 18(1):5-10. PMID: 27809744 [Impact Factor: 3.731]**
217. Jabir NR, Firoz CK, **Ashraf GM**, Zaidi SK, Shakil S, Kamal MA, Tabrez S. Common therapeutic modalities against diabetes and associated cardiovascular disease. **Current Vascular Pharmacology, (2017) 15:365-373. PMID: 28056755 [Impact Factor: 2.583]**
218. Muteeb G, Rehman MT, Ali SZ, Al-Shahrani AM, Kamal MA, **Ashraf GM***. Phage display technique: a novel medicinal approach to overcome antibiotic resistance by using peptide-based inhibitors against β -lactamases. **Current Drug Metabolism, (2017) 18(2): 90-95. PMID: 27465983 [Impact Factor: 3.731]**
219. Azhar A, Ahmad E, Zia Q, Owais M, Rauf MA, **Ashraf GM***. Recent advances in the development of novel protein scaffolds based therapeutics. **International Journal of Biological Macromolecules (2017) 102:630-641. PMID: 28412342 [Impact Factor: 6.953]**
220. Leszek J[#], **Ashraf GM[#]**, Tse WH, Zhang J, Gąsiorowski K, Ávila-Rodríguez MF, Tarasov VV, Barreto GE, Klochkov SG, Bachurin SO, Aliev G. Nanotechnology for Alzheimer Disease. **Current Alzheimer Research (2017) 14(11):1182-1189. PMID: 28164767 [Impact Factor: 3.211]**

221. Roohi, Bano K, Kuddus M, Zaheer MR, Zia Q, Khan MF, **Ashraf GM**, Aliev G. Microbial enzymatic degradation of biodegradable plastics. **Current Pharmaceutical Biotechnology** (2017) 18(5):429-440. PMID: 28545359 [Impact Factor: 1.516]
222. Shevtsova EF, Vinogradova DV, Neganova NE, Avila-Rodriguez M, **Ashraf GM**, Barreto GE, Bachurin SO, Aliev G. Mitochondrial permeability transition pore as a suitable target for neuroprotective agents against Alzheimer's disease. **CNS & Neurological Disorders - Drug Targets** (2017) 16:677-685. PMID: 28440192 [Impact Factor: 2.761]
223. Leszek J, Trypka E, Tarasov VV, **Ashraf GM**, Aliev G. Type 3 diabetes mellitus: a novel implication of Alzheimer's disease. **Current Topics in Medicinal Chemistry**, (2017) 17(12):1331-1335. PMID: 28049395 [Impact Factor: 3.218]
224. Hoseinzadeh E, Makhdoumi P, Taha P, Hossini H, Stelling J, Kamal MA, **Ashraf GM***. A review on nano-antimicrobials: metal nanoparticles, methods, and mechanisms. **Current Drug Metabolism**, (2017) 18(2):120-128. PMID: 27908256 [Impact Factor: 3.731]
225. Gąsiorowski K, Brokos B, Leszek J, **Ashraf GM**, Aliev G. Insulin resistance in Alzheimer's disease: p53 and microRNAs as important players. **Current Topics in Medicinal Chemistry** (2017) 17(12):1429-1437. PMID: 28049397 [Impact Factor: 3.218]
226. Aziz ZA, Ahmad A, Mohd-Setapar SH, Hassan H, Lokhat D, Kamal MA, **Ashraf GM***. Recent advances in drug delivery of polymeric nano-micelles. **Current Drug Metabolism** (2017) 18(1):16-29. PMID: 27654898 [Impact Factor: 3.731]
227. Putta S, Peluso I, Yarla NS, Kilari EK, Bishayee A, Lu DY, Barreto GE, **Ashraf GM**, Scotti L, Scotti MT, Singla RK, Alexiou T, Atanasov AG, Tarasov VV, Bramhachari PV, Imandi SB, Chintala M, Sharma B, Reale M, Filosa R, Aliev G, Kamal MA. Diabetes mellitus and male aging: pharmacotherapeutics and clinical implications. **Current Pharmaceutical Design** (2017) 23(30):4475-4483. PMID: 28831925 [Impact Factor: 2.412]
228. Bhat SA, Kamal MA, Yarla NS, **Ashraf GM***. Synopsis on the management strategies for neurodegenerative disorders: challenges from bench to bedside in successful drug discovery and development. **Current Topics in Medicinal Chemistry**, (2017) 17(12):1371-1378. PMID: 28017151 [Impact Factor: 3.218]
229. Jabir NR, Siddiqui AN, Firoz CK, **Ashraf GM**, Zaidi SK, Khan MS, Shakil S, Alama MN, Kamal MA, Tabrez S. Current updates on therapeutic advances in the management of cardiovascular diseases. **Current Pharmaceutical Design** (2016) 22(5):566-571. PMID: 26601967 [Impact Factor: 3.116]
230. **Ashraf GM^{#,*}**, Ali A^{1, #}, Tabrez S, Zaidi SK, Shakil S, Alam MZ, Rehan M, Aliev G. Linkage of stress with neuromuscular disorders. **CNS & Neurological Disorders – Drug Targets** (2016) 15(3):321-328. PMID: 26831261 [Impact Factor: 2.761]
231. Zia Q, Azhar A, Kamal MA, Aliev G, Owais M, **Ashraf GM***. Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index. **Current Pharmaceutical Design**, (2016) 22(7):792-803. PMID: 26648472 [Impact Factor: 2.412]
232. Chibber S, Athanasios A, Alama MN, Barreto GE, Aliev G, **Ashraf GM***. A synopsis on the linkage between age-related dementias and vascular disorders. **CNS &**

- Neurological Disorders - Drug Targets**, (2016) 15(2):250-258. **PMID:** 26831266 [**Impact Factor:** 2.761]
233. Zaheer MR, Gupta A, Iqbal J, Zia Q, Ahmad A, Roohi, Owais M, Setapar SHM, Hashlmon A, **Ashraf GM**, Aliev G. Molecular mechanisms of drug photodegradation and photosensitization. **Current Pharmaceutical Design**, (2016) 22(7):768-782. **PMID:** 26675230 [**Impact Factor:** 3.116]
234. **Ashraf GM***, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baesa SS, Kamal MA. Recent updates on the association between Alzheimer's disease and vascular dementia. **Medicinal Chemistry**, (2016) 12(3):226-237. **PMID:** 26527156 [**Impact Factor:** 2.53]
235. Khan TA, Hassan I, Ahmad A, Perveen A, Aman S, Quddusi S, Alhazza I M, **Ashraf GM***, Aliev G. Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders. **CNS & Neurological Disorders - Drug Targets**, (2016) 15(3):310-320. **PMID:** 26831262 [**Impact Factor:** 2.761]
236. Sheikh IA, Mirza Z, Ali A, Aliev G, **Ashraf GM***. A proteomics based approach for the identification of gastric cancer related markers. **Current Pharmaceutical Design**, (2016) 22(7):804-811. **PMID:** 26648471 [**Impact Factor:** 3.116]
237. Ali A, Sheikh IA, Mirza Z, Gan SH, Kamal MA, Abuzenadah AM, Damanhour GA, **Ashraf GM***. Application of proteomic tools in modern nanotechnological approaches towards effective management of neurodegenerative disorders. **Current Drug Metabolism** (2015) 16(5):376-388. **PMID:** 25495738 [**Impact Factor:** 3.731]
238. Jabir NR, Firoz CK, Baesa SS, **Ashraf GM**, Akhtar S, Kamal W, Kamal MA, Tabrez S. Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases. **CNS Neuroscience & Therapeutics** (2015) 21(1):1-7. **PMID:** 25399848 [**Impact Factor:** 3.394]
239. Herrera AS, Del C A Esparza M, **Ashraf GM**, Zamyatin AA, Aliev G. Beyond mitochondria, what would be the energy source of the cell? **Central Nervous System Agents in Medicinal Chemistry** (2015) 15(1):32-41. **PMID:** 25645910 [**Impact Factor:**]
240. Soursou G, Athanasios A, **Ashraf GM**, Siyal AA, Mushtaq G, Kamal MA. Applications of nanotechnology in diagnostics and therapeutics of Alzheimer's and Parkinson's disease. **Current Drug Metabolism** (2015) 16(8):705-712. **PMID:** 26560322 [**Impact Factor:** 3.731]
241. **Ashraf GM***, Tabrez S, Jabir NR, Firoz CK, Ahmad S, Hassan I, Athanasios A, Kamal MA. An overview on global trends in nanotechnological approaches for Alzheimer Therapy. **Current Drug Metabolism** (2015) 16(8):719-727. **PMID:** 26560324 [**Impact Factor:** 3.731]
242. **Ashraf GM***, Perveen A, Zaidi SK, Tabrez S, Shakil S, Ahmad A, Haque R, Ahsan J, Kamal MA, Banu N. Integrating qualitative and quantitative tools for the detection and identification of lectins in major human diseases. **Protein and Peptide Letters** (2015) 22(11):954-962. **PMID:** 26419242 [**Impact Factor:** 1.168]
243. Fazili NA, Naeem A, **Ashraf GM**, Gan SH, Kamal MA. Therapeutic interventions for the suppression of Alzheimer's disease: quest for a remedy. **Current Drug Metabolism** (2015) 16(5):346-353. **PMID:** 25429669 [**Impact Factor:** 3.731]

244. Rizvi SMD, Shaikh S, Waseem SMA, Shakil S, Abuzenadah AM, Biswas D, Tabrez S, **Ashraf GM**, Kamal MA. Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease. **EXCLI Journal** (2015) 14:684-696. **PMID: 27152105 [Impact Factor: 2.122]**
245. Athanasios A, Vairaktarakis C, Tsiamis V, **Ashraf GM**. Application of efficient nanoparticles for early diagnosis and treatment of cancer. **Current Drug Metabolism** (2015) 16(8):662-675. **PMID: 26560321 [Impact Factor: 3.731]**
246. Mirza Z, Ali A, **Ashraf GM**, Kamal MA, Abuzenadah AM, Choudhary AG, Damanhoury GA, Sheikh IA. Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. **CNS & Neurological Disorders - Drug Targets** (2014) 13(2):213-225. **PMID: 24059316 [Impact Factor: 2.761]**
247. **Ashraf GM***[#], Greig NH[#], Khan TA, Hassan I, Tabrez S, Shakil S, Sheikh IA, Zaidi SK, Akram M, Jabir NR, Firoz CK, Naeem A, Alhazza IM, Damanhoury GA, Kamal MA. Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. **CNS & Neurological Disorders- Drug Targets** (2014) 13(7):1280-1293. **PMID: 25230234 [Impact Factor: 2.761]**
248. Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, **Ashraf GM**, Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA Jr, Benberin VV, Bachurin SO. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. **Current Medicinal Chemistry** (2014) 21(19):2208-2217. **PMID: 24372221 [Impact Factor: 3.894]**
249. Khan NM, Ahmad A, Tiwari RK, Kamal MA, Mushtaq G, **Ashraf GM***. Current challenges to overcome in the management of type 2 diabetes mellitus and associated neurological disorders. **CNS & Neurological Disorders-Drug Targets** (2014) 13(8):1440-1457. **PMID: 25345504 [Impact Factor: 2.761]**
250. Tabrez S, Priyadarshini M, Urooj M, Shakil S, **Ashraf GM**, Khan MS, Kamal MA, Alam Q, Jabir NR, Abuzenadah AM, Chaudhary AG, Damanhoury GA. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. **Journal of environmental science and health. Part C** (2013) 31(1):67-98. **PMID: 23534395 [Impact Factor: 3.517]**
251. Ahmad A, Rasheed N, Gupta P, Singh S, **Ashraf GM**, Chand K, Maurya R, Palit G. Novel Ocimum sanctum compounds modulate stress response: Role of CRF, POMC, GR and HSP-70 in the hypothalamus and pituitary of rats. **Medicinal Plants** (2013) 5(4):194-201. **PMID: NA [Impact Factor: NA]**
252. Shakil S, Ahmad A, Tabrez S, **Ashraf GM**, Khan AAP, Abuzenadah AM, Kamal MA. A 'region-specific treatment strategy' to address the problem of drug resistance by NDM-1-producing pathogens. **Enzyme Engineering** (2013) 2:1-3. **PMID: NA [Impact Factor: 1.00]**
253. Aliev G, **Ashraf GM**, Kaminsky YG, Sheikh IA, Sudakov SK, Yakhno NN, Benberin VV, Bachurin SO. Implication of the nutritional and nonnutritional factors in the context of preservation of cognitive performance in patients with dementia/depression and Alzheimer disease. **American Journal of Alzheimer's Disease and Other Dementias** (2013) 28(7):660-670. **PMID: 24085255 [Impact Factor: 1.464]**
254. Ali R, Mirza Z, **Ashraf GM**, Kamal MA, Ansari SA, Damanhoury GA, Abuzenadah AM, Chaudhary AG, Sheikh IA. New anticancer agents: recent developments in tumor

therapy. **Anticancer Research** (2012) 32(7):2999-3005. **PMID:** 22753764 [**Impact Factor:** 1.935]

255. Jabir NR, Tabrez S, **Ashraf GM**, Shakil S, Damanhour GA, Kamal MA. Nanotechnology-based approaches in anticancer research. **International Journal of Nanomedicine** (2012) 7:4391-4408. **PMID:** 22927757 [**Impact Factor:** 4.3]
256. Hasan SS, **Ashraf GM**, Banu N. Galectins – Potential targets for cancer therapy. **Cancer Letters**, (2007) 253(1):25-33. **PMID:** 17207926 [**Impact Factor:** 6.508]

Case reports:

257. Herrera AS, Arias Esparza MDC, Arias PES, **Ashraf GM**, Mosa OF, Fisenko VP, Sologova SS, Dostdar SA, Sokolov AV, Bovina EV, Chubarev VN, Tarasov VV, Somasundaram SG, Kirkland CE, Aliev G. The role of melanin to dissociate oxygen from water to treat retinopathy of prematurity. **Central Nervous System Agents in Medicinal Chemistry** (2019) 19(3):215-222. **PMID:** 31267880 [**Impact Factor:**]
258. Herrera AS, Solís-Arias MP, Tarasov VV, **Ashraf GM**, Aliev G. Alopecia areata and medical modulation of the intrinsic property of melanin to transform light into chemical energy through the water dissociation. **Archives of Clinical and Biomedical Research** (2017) 1(3):125-131. **PMID:** [**Impact Factor:** 1.7]

Books:

259. Uddin MS, **Ashraf GM***, eds. Quality control of cellular protein in neurodegenerative disorders. **IGI Global, USA. (2020) ISBN13:** 9781799813170. **ISBN10:** 1799813177. **EISBN13:** 9781799813187. **DOI:** 10.4018/978-1-7998-1317-0.
260. **Ashraf GM***, Alexiou A. eds. Biological, diagnostic and therapeutic advances in Alzheimer's disease: Non-pharmacological therapies for Alzheimer's disease. **Springer Nature Singapore Pte Ltd. (2019) ISBN:** 978-981-13-9635-9. **DOI:** 10.1007/978-981-13-9636-6.
261. **Ashraf GM***, Uddin MS. eds. Advances in dementia research. **Intech Open (2019) ISBN:** 978-1-78985-502-9. **DOI:** 10.5772/intechopen.78252.
262. **Ashraf GM***, Sheikh IA. eds. Advances in protein chemistry. **OMICS Group eBooks (2014). ISBN:** 978-1-63278-016-4. **DOI:** 10.4172/978-1-63278-016-4-017.
263. **Ashraf GM*** Galectins: a research overview. **LAP LAMBERT Academic Publishing (2011). ISBN-10:** 3843388628, **ISBN-13:** 978-384338862.

Book chapters:

264. Cabezas R, Sahebkar A, Echeverria V, Santos JG, **Ashraf GM**, Barreto GE. In silico identification of novel interactions for FABP5 (Fatty Acid-Binding Protein 5) with nutraceuticals: possible repurposing approach. In **Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health, Advances in Experimental Medicine and Biology** (Barreto GE, Sahebkar A. eds.) **Springer Nature Switzerland (2021) 1308:589-599.**
265. Ullah MF, Bhat SH, Tariq M, Abuduhier FM, **Ashraf GM**, Ahmad A. Plant-derived small molecule inhibitors as modulators of EMT pathway in cancer chemoprevention. **Studies in Natural Products Chemistry**, Vol 71 (Rahman AU ed.) **Elsevier, (2021) 45-65.**

266. Alexiou A, Chatzichronis S, **Ashraf GM**. Prediction of Alzheimer's disease. **Diagnosis and Management in Dementia: The Neuroscience of Dementia, Vol. 1** (Martin CR, Preedy VR eds.) **Academic Press (Elsevier), (2020)** 365-378.
267. Chaudhary SS, Chaudhary S, Rawat S, Natesan S, Pardeshi T, Alexiou A, **Ashraf GM***. Recent developments in the etiology, treatment, and potential therapeutic targets for Parkinson's disease: a focus on biochemistry. In **Diagnosis and Management in Parkinson's Disease: The Neuroscience of Parkinson's, Vol. 1** (Martin CR, Preedy VR eds.) **Academic Press (Elsevier), (2020)** 73-90.
268. Ali A, Yangchan J, Ahmad A, Kumar A, Mishra RK, Vyawahare A, **Ashraf GM**, Shakil S, Khan R. A mechanistic perspective on chemopreventive and therapeutic potential of phytochemicals in honey. In **Therapeutic Applications of Honey and its Phytochemicals Vol. 1** (Rehman MU, Majid S eds.) **Springer Nature Singapore Pte Ltd., (2020)** 117-128.
269. Simou P, Vakalos P, Alexiou A, Chatzichronis S, Ali MA, Haranas I, Gkigkitzis I, Hafeez A, Perveen A, **Ashraf GM***. Strengthen Alzheimer's awareness through biomusic. In **Biological, diagnostic and therapeutic advances in Alzheimer's disease (Ashraf GM*, Alexiou A. eds.) Springer Nature Singapore Pte Ltd., (2019)** 117-128.
270. Ali MA, Alexiou A, **Ashraf GM***. Biotechnology and bioinformatics applications in Alzheimer's disease. In **Biological, diagnostic and therapeutic advances in Alzheimer's disease (Ashraf GM*, Alexiou A. eds.) Springer Nature Singapore Pte Ltd., (2019)** 223-234.
271. Chaudhary SS, Choudhary S, Rawat S, Ahir G, Bilgrami AL, **Ashraf GM***. c-Met as a potential therapeutic target in triple negative breast cancer. In **Cancer leading proteases** (Gupta SP, ed.) **Academic Press, Elsevier (2019)** 295-326.
272. Uddin MS, **Ashraf GM***. Introductory Chapter: Alzheimer's disease-The most common cause of dementia. In **Advances in Dementia Research (Ashraf GM*, Uddin MS. eds.) InTechOpen, (2019)** 1-8.
273. Banday ZZ, **Ashraf GM***. Chapter 1- Protein-Protein interactions as potential targets of drug designing. **Advances in Biochemistry & Applications in Medicine** (Shrestha, R. ed.) **Open Access eBooks, (2018)** 3:1-15.
274. Banday ZZ, **Ashraf GM***. Chapter 4- Recent updates on biomarkers of gastric cancer. **Advances in Biochemistry & Applications in Medicine** (Shrestha, R. ed.) **Open Access eBooks, (2018)** 3:1-11.
275. Yarla NS, Sukocheva O, Peluso I, Putta S, Bramhachari PV, Yadala R, Tiwari DK, Jagarlamudi S, Scotti L, Scotti MT, Reale M, Kamal MA, **Ashraf GM**, Sharma B, Parvathaneni M, Rao CV, Mannarapu M, Bishayee A. Targeting arachidonic acid pathway-associated NF- κ B in pancreatic cancer. In **Role of Transcription Factors in Gastrointestinal Malignancies (2018) Springer Nature Singapore Pte Ltd** (Nagaraju, GP, Bramhachari, PV. eds.). 401-409.
276. Korada SK, Yarla NS, Putta S, Hanumakonda AS, Lakkappa DB, Bishayee A, Scotti L, Scotti MT, Aliev G, Kamal MA, Lu DY, Aycan MBY, Reggi R, Palmery M, **Ashraf GM**, Alexiou A, Peluso I. Chapter 1 – A critical appraisal of different food safety and quality management tools to accomplish food safety. In **Food Safety and Preservation-1st Edition- Modern Biological Approaches to Improving Consumer Health, (2018) Academic Press** (Grumezescu AM, Holban AM. eds.), 1–12.

277. Aliev G, Horecký J, Vančová O, **Ashraf GM**, Hassan I, Bragin V, Bragin I, Shevtsova E, Klochkov S, Kosenko EA, Cacabelos R, Bachurin SO, Benberin VV, Kaminsky YG. The three-vessel occlusion as a model of vascular dementia – oxidative stress and mitochondrial failure as an indicator of brain hypoperfusion. In **Systems Biology of Free Radicals and Antioxidants** (Laher, I. ed.), **Springer Berlin Heidelberg**, (2014) 2023-2032.
278. Aliev G, **Ashraf GM**, Horecký J, Vančová O, Gvozdjaková A, Kucharská J, Palacios HH, Li Y, Perveen A, Khan TA, Bragin V, Bragin I, Shevtsova E, Klochkov SG, Kosenko EA, Cacabelos R, Kaminsky YG, Sudakov KV, Benberin VV, Bachurin SO. Potential preventive effects of coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion. In **Systems Biology of Free Radicals and Antioxidants** (Laher, I. ed.), Springer Berlin Heidelberg. (2014) pp 2033-2048.
279. Aliev G, Burzynski G, **Ashraf GM**, Jabir NR, Cacabelos R, Benberin VV, Burzynski SR. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. In **Systems Biology of Free Radicals and Antioxidants** (Laher, I. ed.), Springer Berlin Heidelberg. (2014) pp 2325-2347.
280. Ansari AA, Shaikh S, Muteeb G, Rizvi SMD, Shakil S, Alam A, Tripathi R, Ghazal F, Rehman A, Ali SZ, Pandey AK, **Ashraf GM**. Role of matrix metalloproteinases in cancer. In **Advances in Protein Chemistry** (**Ashraf GM**. and Sheikh IA. ed.), **OMICS Group eBooks** (2013)

Editorial:

281. **Ashraf GM**, Uddin MS. Gene therapy for neuroprotection and neurorestoration (Part III). **Current Gene Therapy** (2020) 21(1):2. **PMID:** [Impact Factor: 2.218]
282. Uddin MS, Athanasios A, Barreto GE, **Ashraf GM**. Neuroproteomics on the rise (Part I). **Current Protein & Peptide Science** (2020) 21(12):1144-1145. **PMID:** 33461450 [Impact Factor: 3.272]
283. Javed MN, **Ashraf GM**, Barreto GE, Naim MJ. Current trends for rationalizing brain targeting nanoparticles in neurological disorders (Part-I). **Current Drug Metabolism** (2020) 21(9):648. **PMID:** 33327901 [Impact Factor: 3.731]
284. **Ashraf GM**, Uddin MS. Gene therapy for neuroprotection and neurorestoration (Part II). **Current Gene Therapy** (2020) 20(3):163. **PMID:** 33054704 [Impact Factor: 2.218]
285. **Ashraf GM**, Uddin MS. Gene therapy for neuroprotection and neurorestoration (Part I). **Current Gene Therapy** (2019) 19(6):358. **PMID:** 32375609 [Impact Factor: 2.218]
286. **Ashraf GM**, Alexiou A. Preface: Biological, diagnostic and therapeutic advances in Alzheimer's disease: Non-pharmacological therapies for Alzheimer's disease. In **Biological, diagnostic and therapeutic advances in Alzheimer's disease** (**Ashraf GM**. and Alexiou A. ed.), **Springer Nature Singapore Pte Ltd.** (2019)
287. Alexiou A, Kamal MA, **Ashraf GM**. Editorial: The Alzheimer's Disease Challenge. **Frontier in Neuroscience** (2019) 13:768. **PMID:** 31396043 [Impact Factor: 3.648]

288. Ashraf GM. Editorial: New emerging trends in protein and peptide based therapeutic approaches- Part II. **Current Protein & Peptide Science** (2018) 19(10):936. PMID: 30101701 [Impact Factor: 3.272]
289. Ashraf GM. Editorial: New emerging trends in protein and peptide based therapeutic approaches- Part I. **Current Protein & Peptide Science** (2018) 19(9):840. PMID: 30027837 [Impact Factor: 3.272]

Abstract:

290. Sheikh IA, Kamal MA, Jiffri EH, Ashraf GM, Beg MA. Isolation and purification of antimicrobial milk proteins. **3rd International Genomic Medicine Conference (3rd IGMC 2015)**: Jeddah, Kingdom of Saudi Arabia. 30 November - 3 December (2015). BMC Genomics 17(S6) July 2016.

Poster:

291. Ashraf GM*. Galectin-1 as potential target for diagnostics and therapeutics: involvement in free radical induced oxidative stress-mediated cardiovascular disorders. **International Conference & Exhibition on Clinical Research Dermatology, Ophthalmology & Cardiology** organized by OMICS Group Conferences on 5-6 July (2011) San Francisco, USA.

Data:

292. Ashraf GM*. (2014) Carbohydrate recognition domain (CRD) sequence of goat heart galectin-1 (GHG-1). **C0HJR3 - LEG1_CAPHI**
(<http://www.uniprot.org/uniprot/C0HJR3>)
293. Ashraf GM*. (2014) Carbohydrate recognition domain (CRD) sequence of buffalo heart galectin-1 (BHG-1). **C0HJQ1 - LEG1_BUBBU**
(<http://www.uniprot.org/uniprot/C0HJQ1>)

EDITORIAL EXPERIENCE:

Journals:

1. Associate Editor in Journal of Advanced Research (Elsevier)
<https://www.journals.elsevier.com/journal-of-advanced-research/editorial-board>
2. Senior Editorial Board Member in Scientific Reports (Nature Publishing Group)
<https://www.nature.com/srep/about/editors#senior-editorial-board>
3. Academic Editor in PLOS ONE (PLOS)
<https://journals.plos.org/plosone/static/editorial-board>
4. Section Editor in Current Neuropharmacology (Bentham)
<https://benthamscience.com/journals/current-neuropharmacology/editorial-board/>
5. Editorial Board Member in Frontiers in Bioscience-Landmark
<https://www.fbscience.com/Landmark/editorial-board>
6. Editorial Board Member in Current Research in Neurobiology
(<https://www.journals.elsevier.com/current-research-in-neurobiology/editorial-board>)
7. Editorial Board Member in Journal of Proteomics (Elsevier)
<https://www.journals.elsevier.com/journal-of-proteomics/editorial-board>

8. Editorial Board Member in Current Protein & Peptide Science (Bentham Science)
<http://www.benthamscience.com/journals/current-protein-and-peptide-science/editorial-board/#top>
9. Editorial Board Member in Frontiers in Pharmacology-ELSI in Science and Genetics
<http://journal.frontiersin.org/journal/all/section/elsi-in-science-and-genetics#editorial-board>
10. Editorial Board Member in Frontiers in Aging Neuroscience-Neurodegeneration
<http://journal.frontiersin.org/journal/all/section/neurodegeneration#editorial-board>
11. Editorial & Advisory Board Member in Biosciences, Biotechnology Research Asia
<http://www.biotech-asia.org/editorial-board/>

Books:

1. Editor in the book titled “Autism spectrum disorder and Alzheimer's disease - advances in research”, (Ashraf GM*, Uddin MS, eds.) Springer Nature (In press).
2. Editor in the book titled “Current thoughts on dementia: from risk factors to therapeutic interventions”, (Ashraf GM*, Uddin MS, eds.) Springer Nature (In press).
3. Editor in the book titled “Neurochemical systems and signaling: from molecules to networks”, (Uddin MS, Ashraf GM*, eds.) CRC Press (In press).
4. Editor in the book titled “Quality control of cellular protein in neurodegenerative disorders”, (Uddin MS, Ashraf GM*, eds.) IGI Global, USA (2020). ISBN13: 9781799813170, ISBN10: 1799813177, EISBN13: 9781799813187, DOI: 10.4018/978-1-7998-1317-0.
5. Editor in the book titled “Biological, diagnostic and therapeutic advances in Alzheimer's disease: Non-pharmacological therapies for Alzheimer's disease”, (Ashraf GM*, Alexiou A, eds.) Springer Nature Singapore Pte Ltd. (2020). eBook ISBN: 978-981-13-9636-6, DOI: 10.1007/978-981-13-9636-6; Hardcover ISBN: 978-981-13-9635-9.
6. Editor in the book titled “Advances in dementia research”, (Ashraf GM*, Uddin MS, eds.) InTechOpen (2019). ISBN: 978-1-78985-502-9.
7. Editor in the eBook titled “Advances in Protein Chemistry”, (Ashraf GM*, Sheikh I. eds.) Omics Group Incorporation, USA (2013). ISBN: 978-1-63278-016-4, DOI: 10.4172/978-1-63278-016-4-017.
8. Editorial Advisory Board Member in the book “Handbook of Research on Critical Examinations of Neurodegenerative Disorders” (Uddin MS, Arman MS, eds.) Advances in Medical Diagnosis, Treatment, and Care (AMDTC) Book Series (2018). ISBN13: 9781522552826, ISBN10: 1522552820, EISBN13: 9781522552833, DOI: 10.4018/978-1-5225-5282-6.

Special issues:

1. Guest Editor in the special issue titled “Mitochondrial Medicine for Neurological Disorders” in the journal ‘Current Neuropharmacology’ (IMR Press) (Bentham Science).
2. Guest Editor in the special issue titled “Oxidative Stress in Neurodegenerative Disorders” in the journal ‘Frontiers in Bioscience-Landmark’ (IMR Press) (2021-2022).
(<https://www.fbscience.com/Landmark/special-issue/1396744728988798978>)

3. Guest Editor in the special issue titled “Natural products for neurological disorders” in the journal ‘Journal of Integrative Neuroscience’ (IMR Press) (2021-2022).
(<https://jin.imrpress.com/EN/subject/listSubjectChapters.do?subjectId=1618536851782>)
4. Guest Editor in the special issue titled “Biomedical informatics in neuroscience” in the journal ‘Journal of Integrative Neuroscience’ (IMR Press) (2021-2022).
(<https://jin.imrpress.com/EN/subject/listSubjectChapters.do?subjectId=1611653500838>)
5. Guest Editor in the special issue titled “Theme Issue Honoring Professor Philippe Jeandet’s 60th Birthday: Bioactivity and Chemical Diversity of Natural Compounds” in the journal ‘Molecules’ (MDPI) (2020-2021).
(https://www.mdpi.com/journal/molecules/special_issues/NPC_Professor_Philippe_Jeandet)
6. Guest Editor in the special issue titled “Application of Natural Products in Experimental, and Cheminformatics-based Therapy for Neurological Disorders” in the journal ‘Evidence-Based Complementary and Alternative Medicine’ (Hindawi) (2020-2021).
(<https://www.hindawi.com/journals/ecam/si/471062/>)
7. Guest Editor in the special issue titled “Cytokine Storm and Amyloid Pathology Including Viral Infection in Neurological Infections” in the journal ‘Mediators of Inflammation’ (Hindawi) (2020-2021).
(<https://www.hindawi.com/journals/mi/si/951327/>)
8. Guest Editor in the special issue titled “Mitochondrial dysfunction and traffic jams in neurodegenerative disorders” in the journal ‘Current Drug Targets’ (Bentham Science) (2020-2021).
9. Guest Editor in the special issue titled “Gene therapy for neuroprotection and neurorestoration in neurological disorders (Part III)” in the journal ‘Current Gene Therapy’ (Bentham Science) (2020-2021).
10. Guest Editor in the special issue titled “Current trends for rationalizing brain targeting nanoparticles in neurological disorders” in the journal ‘Current Drug Metabolism’ (Bentham Science) (2019-2020).
11. Guest Editor in the special issue titled “Neuroproteomics on the rise” in the journal ‘Current Protein and Peptide Science’ (Bentham Science) (2019-2020).
12. Guest Editor in the special issue titled “Gene therapy for neuroprotection and neurorestoration in neurological disorders (Part II)” in the journal ‘Current Gene Therapy’ (Bentham Science) (2019-2020).
13. Guest Editor in the special issue titled “Gene therapy for neuroprotection and neurorestoration in neurological disorders (Part I)” in the journal ‘Current Gene Therapy’ (Bentham Science) (2019-2020).
14. Guest Editor in the special issue titled “New emerging trends in protein and peptide based therapeutic approaches (Part I)” in the journal ‘Current Protein and Peptide Science’ (Bentham Science) (2017-2018).
15. Guest Editor in the special issue titled “New emerging trends in protein and peptide based therapeutic approaches (Part II)” in the journal ‘Current Protein and Peptide Science’ (Bentham Science) (2017-2018).

16. Research Topic Editor in Research Topic titled “The Alzheimer’s Disease Challenge” in Frontiers (2017-2018).

REVIEWING EXPERIENCE:

1. International project assessment of research proposal for Alzheimer Research Foundation “*Perturbation of apolipoprotein E4 (apoE4) activity in AD pathology using single domain antibodies and targeting them to brain*” submitted by Prof. Dr. Jan Gettemans (Ghent University, Belgium) (2020).
2. International project assessment of research proposal for the National Research Foundation titled “*Inhibition of South African HIV protease subtype C (CSA HIV PR) using the potent peptidomimetic inh*” submitted by Dr Bahareh Honarparvar (University of KwaZulu-Natal, South Africa) (2017).
3. International project assessment of research proposal for the National Research Foundation (SA Research Chairs) titled “*Natural Products green biotechnology*” submitted by Prof Ahmad Mohammed (Cape Peninsula University of Technology, South Africa) (2017).
4. **Reviewer in Journals:** Ageing Research Reviews, American Journal of Alzheimer's Disease and Other Dementias, Applied Biochemistry and Biotechnology, Bioanalysis, Biomaterials, CNS and Neurological Disorders- Drug Targets, BMC Neuroscience, Current Drug Metabolism, Current Medicinal Chemistry, Current Alzheimer’s Research, Evidence-Based Complementary and Alternative Medicine, Frontiers-ELSI in Science and Genetics, Frontiers in Neuroscience-Neurodegeneration, Frontiers in Aging Neuroscience, Interdisciplinary Sciences: Computational Life Sciences, International Journal of Biological Macromolecules, Journal of Proteomics, PLOS One, Medicinal Chemistry, Molecular Biology Reports, Neurobiology of stress, The Protein Journal, Protein and Peptide Letters, Process Biochemistry, Scientific Reports.

EXAMINING EXPERIENCE:

1. External examiner in M.Sc. thesis titled “Angiogenesis biomarkers in ischemic stroke patients” submitted by Mr. Yasser Abdul-Rahman Almohaya under the guidance of Dr. Talal Qadah (King Abdulaziz University, Saudi Arabia) (2020).
2. External examiner in M.Sc. thesis titled “Toxicity of carbon nanotubes on tomato *Solanum lycopersicum L.*” submitted by Ms. Shyma Own Ali Al-Qarni under the guidance of Prof. Sameera O. Bafeel (King Abdulaziz University, Saudi Arabia) (2020).
3. External examiner in M.Sc. thesis titled “Angiogenic biomarkers in pregnancy associated with gestational diabetes” submitted by Mr. Salman Mousa A Muyidi under the guidance of Dr. Azizah Alrafiah (King Abdulaziz University, Saudi Arabia) (2020).
4. External examiner in M.Sc. thesis titled “Drug abuse-related biomarkers that accelerate neurodegenerative disorders” submitted by Mr. Mohammad Mousa Abu-Illah under the guidance of Dr. Azizah Alrafiah (King Abdulaziz University, Saudi Arabia) (2020).
5. External examiner in M.Sc. thesis titled “Parkinson’s disease related biomarkers that may appear in amphetamine abusers” submitted by Mr. Abdulaziz Mohammed M Al-Kaabi under the guidance of Dr. Azizah Alrafiah (King Abdulaziz University, Saudi Arabia) (2020).

6. External examiner in Ph.D. thesis titled “Molecular Modeling Studies on Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors (NNRTIs)” submitted by Mr. Bilal Nizami under the guidance of Dr. Bahareh Honarparvar (University of KwaZulu-Natal, South Africa) (2016).

SCIENTIFIC MEETINGS:

1. Ashraf GM. “*Understanding the behavioral and molecular mechanism of effects of antipsychotic and antidiabetic drugs in psychotic conditions*” at International webinar on psychiatry, Alzheimer’s and dementia (5th October 2020). [Oral presentation]
2. Royal Society of Biology Annual General Meeting 2020 (24 September 2020).
3. Scientific Event of “*Special Infectious Agents Unit*” organized by King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia (18-19th December 2019).
4. Ashraf GM, Perveen A. “*Investigation of expression patterns of neurological proteins in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders*” at 13th Annual Conference on Dementia and Alzheimer’s Disease organized by Conferenceseries LLC Ltd at Abu Dhabi, UAE (December 13-15, 2018). [Oral presentation]
5. Training program on “*Basics of E-learning management system*” organized by Deanship of E-learning and Distance Education, King Abdulaziz University, Jeddah, Saudi Arabia (20-21th January 2016).
6. Training course on “*How to publish your results*” organized by The Vice Presidency for Graduate Studies and Scientific Research, King Abdulaziz University, Jeddah, Saudi Arabia (13th April 2015).
7. Training program on “*Basics of E-learning management system*” organized by Deanship of E-learning and Distance Education, King Abdulaziz University, Jeddah, Saudi Arabia (28-29th October 2014).
8. Workshop on “*Principles of student assessment*” organized by Center for Teaching and Learning Development, King Abdulaziz University, Jeddah, Saudi Arabia (24th April 2014).
9. Geriatric-1 session chair at 1st World Congress on Geriatrics and Neurodegenerative Diseases Research, organized by Department of Informatics, Ionian University, Corfu, Greece (April 10-13, 2014).
10. Ashraf GM, Perveen A, Tabrez S, Jabir NR, Damanhoury GA, Zaidi SK, Banu N. “*Altered galectin glycosylation: potential factor for the diagnostics and therapeutics of various cardiovascular and neurological disorders*” at 1st World Congress on Geriatrics and Neurodegenerative Diseases Research, organized by Department of Informatics, Ionian University, Corfu, Greece (10-13 April 2014). [Oral presentation]
11. Ashraf GM, Rizvi S, Naqvi S, Suhail N, Bilal N, Hasan S, Tabish M and Banu N. “*Purification, characterization, structural analysis and protein chemistry of a buffalo heart galectin-1*” at Biosparks 2010- VIIIth Annual Research Festival of School of Life Sciences, Jawaharlal Nehru University, New Delhi, India (11-12 March 2010). [Poster presentation]
12. Ashraf GM, Bilal N, Suhail N, Hasan S and Banu N. “*Glycosylation plays a vital role in maintaining the structural and functional integrity of a galectin-1 purified from Capra*

- hircus heart*” in National Symposium on “Recent trends in enzyme technology, toxicology and bioinformatics” under the auspices of UGC-DRS II programme of the Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India (March 3, 2010). [Poster presentation]
13. Ashraf GM, Suhail N, Bilal N, Hasan S and Banu N. “*Studies on the activation of oxidative burst and degranulation of neutrophils by goat heart lectin, N-formyl-L-methionyl-L-leucyl-L-phenylalanine and phorbol 12-myristate 13-acetate*” at Society of Free Radical Research (SFRR) Satellite India 2008 Conference on "Free radicals in health and disease" at Department of Biochemistry, Aligarh Muslim University, Aligarh, India (March 17-18, 2009). [Poster presentation]
 14. Ashraf GM, Banu N. “*Immunological studies of a galectin-1 purified from buffalo heart*”. National symposium on Advances in Clinical Biochemistry- Biomarkers, Molecular Diagnosis and Quality Assurances & 1st U.P. chapter of Association of Clinical Biochemists of India (UPACBICON)” organized by Department of Biochemistry, Faculty of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India (15-16th November 2008). [Poster presentation]
 15. Ashraf GM, Banu N. “*Glycosylation plays a vital role in maintaining the structural and functional integrity of a galectin-1 purified from buffalo heart*”. National symposium on “Recent advances in biochemistry and allied sciences” organized by Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India (25th March 2008). [Poster presentation]
 16. Ashraf GM and Banu N. “*Isolation, purification and physicochemical characterization of soluble β -galactoside binding lectin from goat (*Capra hircus*) heart*” at Society of Free Radical Research (SFRR) Satellite India Conference on “Free radicals and antioxidants in human health, gene regulation and signal transduction” organized by Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India (Feb 11-12, 2008). [Poster presentation]
 17. Ashraf GM and Banu N. “*Isolation, purification and physicochemical characterization of soluble β -galactoside binding lectin from buffalo (*Bubalus bubalis*) heart*” in International Symposium on the “Predictive, Preventive and Mechanistic Mutagenesis” organized by Department of Agricultural Microbiology, Aligarh Muslim University, Aligarh, India (Jan 1-3, 2008). [Poster presentation]
 18. BD FACS Calibur basic training workshop during international symposium on “*Predictive, preventive and mechanistic mutagenesis*” at the Department of Agricultural Microbiology, Faculty of Agricultural Science, Aligarh Muslim University, India (2nd Jan 2008).
 19. Second international symposium on “*Translational research on natural products and cancer*” held at Lonavala, Mumbai, India (Dec 9-12, 2007).
 20. “*South Asian and seventh annual national conference of Indian congress of forensic medicine and toxicology*” organized by Department of Forensic Medicine and Toxicology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India (March 24-25, 2007).
 21. International workshop on “*Joint Biology and Disease*” organized by Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, India (March 17-18, 2007).

22. DBT sponsored workshop on “*Genome Analysis: A Bioinformatics Approach*” organized by Distribution Information Sub-Centre, Aligarh Muslim University, Aligarh, India (Feb 24-25, 2007).

IT SKILLS:

Operating systems: Windows 98, 2000, XP, Vista, Seven, Ten; Origin 6.1, Sigma Plot.

MS Office tools: MS Word, MS Excel, MS PowerPoint, Microsoft teams

Softwares: Biorender, Endnote, Graphpad Prism, Origin.

Statistical analysis: SPSS-Student's t-test, ANOVA.

PERSONAL DETAILS:

Gender: Male

Nationality: Indian

Date of Birth: 25.12.1984

Passport number: T3909908

Father's Name: Nayeemuddin

Mother's name: Rokaiya Khatoon

Wife's name: Asma Perveen

Children: 3 (Sameeha Ashraf, 8y; Abdullah Ashraf, 5y; Mustafa Ashraf, 2y)

REFEREES:

1. Prof. Ahmad Waseem

Centre for Immunobiology and Regenerative Medicine,
Blizard Institute, 4 Newark Street, London E1 2AT, United Kingdom
Email: a.waseem@qmul.ac.uk, Contact no.: +447779879236

2. Dr. Fahim Halim Khan

Associate Professor, Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, India
Email: fahimhalimkhan@hotmail.com, Contact no.: +919897151654

3. Dr. George E Barreto

Lecturer, Department of Biological Sciences,
University of Limerick, Limerick, V94 T9PX, Ireland
Email: george.Barreto@ul.ie, Contact no.: +353834157806